Implications of Primary Cilia and Associated Lysophosphatidic Acid Signaling in Glioblastoma Biology and Therapy

Yuriy V. Loskutov

Follow this and additional works at: https://researchrepository.wvu.edu/etd

Recommended Citation
Loskutov, Yuriy V., "Implications of Primary Cilia and Associated Lysophosphatidic Acid Signaling in Glioblastoma Biology and Therapy" (2017). Graduate Theses, Dissertations, and Problem Reports. 6113. https://researchrepository.wvu.edu/etd/6113

This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact researchrepository@mail.wvu.edu.
Implications of primary cilia and associated lysophosphatidic acid signaling in glioblastoma biology and therapy.

Yuriy V. Loskutov

Dissertation Submitted
to the School of Medicine
at West Virginia University

In Partial Fulfillment of the Requirements
for the Degree of

Doctor of Philosophy in
Cancer Cell Biology

Michael Schaller, Ph.D., Chair
Michael Ruppert, Ph.D.
Karen Martin, Ph.D.
Maxim Sokolov, Ph.D.
Peter Stoilov, Ph.D.
Elena Pugacheva, Ph.D., Mentor

Cancer Cell Biology Program
Morgantown, West Virginia
2017

Keywords: LPA, primary cilia, LPAR1, GBM
Copyright 2017 Yuriy Loskutov
Abstract

Implications of primary cilia and associated lysophosphatidic acid signaling in glioblastoma biology and therapy.

Yuriy Loskutov

The primary cilium is a ubiquitous organelle presented on most human cells. It serves as a crucial signaling hub for multiple pathways including growth factor and G-protein coupled receptors. Loss of primary cilia was observed in various cancers, however, the implications of this event are unclear. Several studies show that loss of cilia promotes cell proliferation, suggesting that alteration of ciliary-dependent signaling can drive the hyper-proliferative phenotype of cancer cells, therefore re-establishing primary cilia or targeting altered signaling pathways could be a beneficial strategy as an anti-cancer therapy.

Glioblastoma (GBM) is one of the deadliest cancers with a median survival of 14 months. Such rapid progression of the disease is usually due to the very high growth rate of the tumor and rapid recurrence after surgical resection. Current standard of care for GBM patients includes aggressive radiation and chemotherapy, thus there is a high demand for more targeted approaches. Primary cilia formation is drastically decreased in GBM, however, the role of cilia in glioblastoma proliferation has not been explored. The overall aim of this work was to elucidate the mechanisms of increases in proliferation driven by the loss of cilia, and utilize it to target GBM. The cellular origins of GBM are currently under debate. One of the potential candidates are astrocytes, a highly abundant type of cell in the brain. Loss of primary cilia in human astrocytes stimulates proliferation in the presence of serum. Lysophosphatidic acid (LPA) was found to be a serum component responsible for this phenotype. Lysophosphatidic acid receptor 1 (LPAR1), a G-protein coupled receptor, was found to be accumulated in primary cilium in both astrocytes and GBM cells when cilium was present, while previously reported interactors of LPAR1, Gα12 and Gαq, were excluded from cilium. LPAR1 signaling through Gα12/Gαq was previously reported to be responsible for cancer cell proliferation. Such compartmentalization in ciliated cells creates a barrier against unlimited proliferation, which is one of the hallmarks of cancer.

Inhibition of LPA signaling with the small molecule compound Ki16425 in deciliated, highly proliferative astrocytes or GBM cells/xenografts drastically suppresses their growth both in vitro and in vivo. Moreover, Ki16425 brain delivery via PEG-PLGA nanoparticles inhibited tumor progression in an intracranial glioblastoma patient-derived xenograft (PDX) model. Overall, in the current studies, a novel mechanism by which primary cilium restricts proliferation was established. Loss of primary cilia is sufficient to increase mitogenic signaling, and is important for the maintenance of a highly proliferative cancer phenotype. Clinical application of LPA inhibitors may prove beneficial to restrict glioblastoma proliferation and ensure local control of the disease.
Acknowledgements

I would like to thank my advisor Dr. Elena Pugacheva for being patient and understanding, for pushing me to achieve more, and for supporting me through all the perils of research.

I would also like to acknowledge my graduate committee for their guidance and constant support, and Dr. Andrey Bobko and Dr. Werner Geldenhuyys for invaluable methodological support.

I would like to acknowledge all of the current and past lab members of the Pugacheva lab for their objective opinions and critiques, very special thanks go to Brandon Jones for his perfect editorial skills.

Finally, I would like to thank Maria Voronkova for putting up with me for so long and being a faithful companion and friend.
# Table of Contents

Abstract ...................................................................................................................... ii  
Acknowledgements ................................................................................................. iii  
Table of Contents ..................................................................................................... iv  
List of Figures .......................................................................................................... vi  
Glossary .................................................................................................................... viii  

**Literature Review** .................................................................................................. 1  

1. Primary cilia: signaling hub/organelle/molecular machine .................. 1  
   1.1 Primary cilia structure, maintenance, and function  
   1.2 Mechanisms of assembly/disassembly of primary cilia  
   1.3 Primary cilia and signal transduction in mammalian cells  
   1.4 Primary cilia loss/dysfunction-associated diseases-ciliopathies  
2. Primary cilia: potential target for anti-cancer therapy ..................... 6  
   2.1 Primary cilia and cancer  
   2.2 Glioblastoma and primary cilia  
3. LPA signaling in mammalian cells ......................................................... 8  
   3.1 LPA production and signaling  
   3.2 LPA receptors: expression function and regulation  
   3.3 LPA/LPAR signaling in cancer  
4. Kinesin13 family motors and their role in cancer ......................... 10  
   4.1 Kinesin motor superfamily in regulation of microtubule dynamics  
   4.2 Cellular function of Kinesin-13 family members  
   4.3 Kinesin-13 family members in cancer  
5. Aurora kinase A: master regulator of cilium ................................. 15  
   5.1 AURKA structure and function  
   5.2 Role of AURKA in regulation of the ciliary dynamics  
   5.3 LPA/LPAR signaling in cancer  

References
List of Figures

Introduction

1. Principal components and organization of the primary cilium.
2. Schematic of LPAR signaling.

Study 1

4. Loss of primary cilia promotes astrocyte proliferation in a growth factor-dependent manner.
5. Loss of cilium promotes increased ERK1/2 phosphorylation in response to serum stimulation.
7. Lysophosphatidic acid promotes proliferation in deciliated astrocytes.
8. Intracellular localization of LPA signaling cascade components.
9. Inhibition of LPA signaling suppresses proliferation of GBM PDXs in vivo.

Supplementary figures:
S1. Primary cilia formation in human astrocytes and astrocytes immortalized with large T antigen.
S2. Proliferation and ERK1/2 and AKT phosphorylation in response to single growth factor stimulation of HA-LTA.
S3. Proliferation and ERK1/2 and AKT phosphorylation in response to single growth factor stimulation of HA-LTA.
S4. LPAR1, 3 and 6 subcellular localization in cells with assembled primary cilium.
S5. LPAR1, 3 and 6 subcellular localization in cells with disassembled primary cilium.
S6. LPAR1 antibodies validation for immunofluorescent staining.
S7. Endogenous LPAR1 localization in cells with and without primary cilium.
S8. GBM6 and GBM12 have decreased ciliation and utilize LPA as a growth factor.

S9. Administration of Ki16425 has no effect on intracranial tumor growth.

Study 2

1. KIF2C overexpression drives cilia disassembly in an AURKA-dependent manner.
2. Stem-cell/differentiation marker status of ciliated cells is different from cells without primary cilia.
3. Effects of KIF2C depletion and inhibition of AURKA on GBM cells proliferation and ciliation.
## Glossary

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>GBM</td>
<td>glioblastoma multiforme</td>
</tr>
<tr>
<td>LPA</td>
<td>lysophosphatidic acid</td>
</tr>
<tr>
<td>LPAR</td>
<td>lysophosphatidic acid receptor</td>
</tr>
<tr>
<td>PDX</td>
<td>patient derived xenograft</td>
</tr>
<tr>
<td>PEG-PLGA</td>
<td>poly(ethylene glycol)- poly(lactide-co-glycolide)</td>
</tr>
<tr>
<td>ERK1/2</td>
<td>extracellular signal–regulated kinase1/2</td>
</tr>
<tr>
<td>AKT</td>
<td>protein kinase B</td>
</tr>
<tr>
<td>pAKT</td>
<td>phosphorylated protein kinase B</td>
</tr>
<tr>
<td>HA</td>
<td>human astrocytes</td>
</tr>
<tr>
<td>HA-LTA</td>
<td>human astrocytes immortalized with SV40 large T antigen</td>
</tr>
<tr>
<td>SV40</td>
<td>Simian vacuolating virus 40</td>
</tr>
<tr>
<td>IFT</td>
<td>intraflagellar transport</td>
</tr>
<tr>
<td>BBS</td>
<td>Bardet-Biedl syndrome</td>
</tr>
<tr>
<td>BBSome</td>
<td>complex of BBS proteins</td>
</tr>
<tr>
<td>KAP</td>
<td>kinesin accessory protein</td>
</tr>
<tr>
<td>AURKA</td>
<td>aurora kinase A</td>
</tr>
<tr>
<td>AURKB</td>
<td>aurora kinase B</td>
</tr>
<tr>
<td>AURKC</td>
<td>aurora kinase C</td>
</tr>
<tr>
<td>NEDD9</td>
<td>neural precursor cell expressed developmentally down-regulated protein 9</td>
</tr>
<tr>
<td>HDAC6</td>
<td>histone deacetylase 6</td>
</tr>
<tr>
<td>Plk1</td>
<td>polo-like kinase 1</td>
</tr>
<tr>
<td>CCRK</td>
<td>cell cycle related kinase</td>
</tr>
<tr>
<td>ICK</td>
<td>intestinal cell kinase</td>
</tr>
<tr>
<td>MAK</td>
<td>male germ cell-associated kinase</td>
</tr>
<tr>
<td>Shh</td>
<td>Sonic Hedgehog</td>
</tr>
<tr>
<td>Ptch1</td>
<td>patched 1</td>
</tr>
<tr>
<td>Smo</td>
<td>smoothened</td>
</tr>
<tr>
<td>PKA</td>
<td>protein kinase A</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>RTK</td>
<td>receptor tyrosine kinase</td>
</tr>
<tr>
<td>PDGFR</td>
<td>platelets derived growth factor receptor</td>
</tr>
<tr>
<td>PDGF</td>
<td>platelets derived growth factor</td>
</tr>
<tr>
<td>IGF1R</td>
<td>insulin-like growth factor 1 receptor</td>
</tr>
<tr>
<td>EGFR</td>
<td>epidermal growth factor receptor</td>
</tr>
<tr>
<td>FGFR</td>
<td>fibroblast growth factor receptor</td>
</tr>
<tr>
<td>GPCR</td>
<td>G-protein coupled receptor</td>
</tr>
<tr>
<td>AC</td>
<td>adenylyl cyclase</td>
</tr>
<tr>
<td>JBTS</td>
<td>Joubert Syndrome</td>
</tr>
<tr>
<td>ATX</td>
<td>autotoxin</td>
</tr>
<tr>
<td>LPC</td>
<td>Lysophosphatidylcholine</td>
</tr>
<tr>
<td>Arf</td>
<td>ADP ribosylation factor</td>
</tr>
<tr>
<td>ADP</td>
<td>adenosine diphosphate</td>
</tr>
<tr>
<td>GAP</td>
<td>GTPase-activating proteins</td>
</tr>
<tr>
<td>GTP</td>
<td>Guanosine triphosphate</td>
</tr>
<tr>
<td>AGAP1</td>
<td>ArfGAP with GTPase Domain, Ankyrin Repeat And PH Domain 1</td>
</tr>
<tr>
<td>EB1/3</td>
<td>end binding protein1/3</td>
</tr>
<tr>
<td>TPX2</td>
<td>differentially expressed in cancerous and non-cancerous lung cells 2</td>
</tr>
<tr>
<td>PP2a</td>
<td>serine/threonine protein phosphatase 2A</td>
</tr>
<tr>
<td>Cdk1</td>
<td>cyclin-dependent kinase 1</td>
</tr>
<tr>
<td>Pifo</td>
<td>protein pitchfork</td>
</tr>
<tr>
<td>Nek2</td>
<td>NIMA related kinase 2</td>
</tr>
<tr>
<td>SFM</td>
<td>serum free media</td>
</tr>
<tr>
<td>SSM</td>
<td>serum supplemented media</td>
</tr>
<tr>
<td>cSSM</td>
<td>charcoal stripped serum supplemented media</td>
</tr>
<tr>
<td>EGF</td>
<td>epidermal growth factor</td>
</tr>
<tr>
<td>bFGF</td>
<td>basic fibroblast growth factor</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>HGF</td>
<td>hepatocyte growth factor</td>
</tr>
<tr>
<td>CRISPR-Cas9</td>
<td>clustered regularly interspaced short palindromic repeats associated protein Cas9</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>PTEN</td>
<td>phosphatase and tensin homolog</td>
</tr>
<tr>
<td>DMEM/F12</td>
<td>Dulbecco’s modified Eagle medium/nutrient mixture F-12 50/50 mixture</td>
</tr>
<tr>
<td>FBS</td>
<td>fetal bovine serum</td>
</tr>
<tr>
<td>MTA</td>
<td>material transfer agreement</td>
</tr>
<tr>
<td>BSA</td>
<td>bovine serum albumin</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>HRP</td>
<td>horseradish peroxidase</td>
</tr>
<tr>
<td>F-IHC</td>
<td>fluorescent immunohistochemistry</td>
</tr>
<tr>
<td>TBS</td>
<td>tris-buffered saline</td>
</tr>
<tr>
<td>HMEC</td>
<td>human mammary epithelial cells</td>
</tr>
<tr>
<td>NSG</td>
<td>NOD.Cg-Prkdc&lt;sup&gt;scid&lt;/sup&gt; I2rg&lt;sup&gt;im1Wjl/SzJ&lt;/sup&gt; (NSG) immunodeficient mice</td>
</tr>
<tr>
<td>DPBS</td>
<td>Dulbecco’s phosphate-buffered saline</td>
</tr>
<tr>
<td>PBS</td>
<td>phosphate-buffered saline</td>
</tr>
<tr>
<td>DMSO</td>
<td>dimethyl sulfoxide</td>
</tr>
<tr>
<td>WVU IACUC</td>
<td>West Virginia University Institutional Animal Care and Use Committee</td>
</tr>
<tr>
<td>DTPA</td>
<td>diethylenetriaminepentaacetic acid</td>
</tr>
<tr>
<td>RPE1 hTert</td>
<td>retinal pigmented epithelial cells immortalized with human telomerase</td>
</tr>
<tr>
<td>ATCC</td>
<td>American Type Culture Collection</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>ANOVA</td>
<td>analysis of variance</td>
</tr>
<tr>
<td>AcTub</td>
<td>acetylated α-tubulin</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------</td>
</tr>
<tr>
<td>γTub</td>
<td>γ-tubulin</td>
</tr>
<tr>
<td>shRNA</td>
<td>short hairpin RNA</td>
</tr>
<tr>
<td>RNA</td>
<td>ribonucleic acid</td>
</tr>
<tr>
<td>GAPDH</td>
<td>glyceraldehyde 3-phosphate dehydrogenase</td>
</tr>
<tr>
<td>MCS</td>
<td>multiple cloning site</td>
</tr>
<tr>
<td>Sox2</td>
<td>sex determining region Y-box 2</td>
</tr>
<tr>
<td>CD44</td>
<td>hyaluronate receptor</td>
</tr>
<tr>
<td>Dox</td>
<td>doxycycline</td>
</tr>
<tr>
<td>DAPI</td>
<td>4′,6-Diamidino-2-Phenylindole, Dihydrochloride</td>
</tr>
</tbody>
</table>
Literature Review

1. Primary cilia: signaling hub/organelle/molecular machine

1.1 Primary cilia structure, maintenance, and function

Primary cilia is a non-motile, microtubule-based organelle. It is formed as a protrusion of a mature centriole in G1/G0, consists of nine doublets of microtubules known as an axoneme, and is covered with the plasma membrane (1) (Fig. 1). Ciliary microtubules are built from tubulin α and β dimers with the “+” end located at the tip of the cilium. The axoneme includes a transition zone linking the cilium to the centriole/basal body, a doublet zone including both microtubule doublet A (full microtubule) and B (hemitube), and a singlet zone where only A tubes are present (2). The base of the primary cilium usually emerges from an invagination in the cell plasma membrane known as the ciliary pocket (3).

![Figure 1. Principal components and organization of the primary cilium.](image)

Cilia accumulate multiple receptors and signal transduction components, thus tight regulation of ciliary trafficking is required. Indeed, an elaborate system of intraflagellar transport machinery exists, and the core components of this system are intraflagellar...
transport (IFT) particles (Fig.1). IFT particles consist of motor proteins, IFT-A, IFT-B, and BBSome complexes (4). Motor proteins include heterodimeric kinesin II complex (KIF3A, KIF3B and KAP), homodimeric kinesin II complex (KIF17), and IFT dynein complex. Heterodimeric kinesin II is required for cilium assembly (5) and movement of the IFT particles along the doublet zone (6). Homodimeric kinesin II seems to be dispensable for cilium assembly (7) and is required for movement along the singlet zone of the axoneme (6). IFT-dynein propels the IFT particles from the tip of the cilium back to the cell body (8). Loss of IFT-dynein results in abnormal, bulging cilia with accumulation of the IFT particles at the tip (9, 10). IFT-A and IFT-B complexes form the core of IFT particles, however, the exact function and relation of their components are not clear (11). Several components, such as IFT88, were reported to be essential for cilium assembly (12). The BBSome complex derives its name from Bardet-Biedl syndrome, since mutations in its components cause this disease (13). The BBSome interacts with IFT-A and IFT-B complexes and is believed to participate in trafficking of the transmembrane proteins along the cilium (14).

1.2 Mechanisms of assembly/disassembly of primary cilia

Assembly of the primary cilium begins in G1 with a docking of the small cytoplasmic vesicles to the mother centriole, this is Cep164 and Talpid3-dependent event (15). The fusion of the small vesicles, which requires EDH1 and EDH3, generates a large ciliary vesicle encapsulating the growing axoneme (16). After the assembly of the large ciliary vesicle, Rabin 8 activates Rab8, which promotes cilium elongation (16). Elongation of the axoneme deforms the ciliary vesicle by creating two membrane surfaces: the sheath (outer membrane) and the shaft (membrane surrounding axoneme). After the docking of the mother centriole to the plasma membrane, the ciliary vesicle fuses with it, exposing the growing cilium to the extracellular environment (17).

Disassembly of the primary cilium is a crucial event for cell cycle progression. As the cilium is a protrusion of the basal body, it anchors the centriole in the perimembrane area, thereby preventing it from participation in mitotic spindle formation (18). During the cell cycle, the cilium is assembled in the G1/G0 phase, fluctuates through S and G2, and gets disassembled during G2/M transition (19). It is not entirely clear what is the mechanism
of cilium disassembly, however, there are several lines of evidence suggesting complex regulation of this process. Activation of the mitotic kinase Aurora A (AURKA) is a key player in cilium disassembly, and inhibition or transient depletion of AURKA abolishes serum-initiated cilia disassembly. The scaffold protein NEDD9, also known as neural precursor cell expressed developmentally down-regulated protein 9, has been implicated in the activation of AURKA (20) and is required for cilium disassembly. Histone deacetylase 6 (HDAC6), an enzyme that deacetylates tubulin (21), is a known phosphorylation target of AURKA, which increases its deacetylase activity and destabilizes axonemal microtubules (19). Interestingly, the role of HDAC6 seems to be dispensable for cilia development, arguing that cilium can be disassembled without HDAC6 involvement (22). The microtubule-destabilizing kinesins KIF2A and KIF2C are potential candidates for direct disassembly of axonemal microtubules. Overexpression of both kinesins triggers cillum disassembly, and KIF2A activity towards cilia is regulated by polo-like kinase 1 (Plk1) (23). Plk1 is a well-known target of AURKA (24), and moreover, both KIF2A and KIF2C are known to be regulated by AURKA during mitosis (25, 26), which puts them in the same AURKA-driven pathway for cilium disassembly. Cell cycle related kinase (CCRK) and its substrates intestinal cell kinase (ICK) and male germ cell-associated kinase (MAK) were reported to participate in cilium disassembly (27). Furthermore, CCRK has been implicated in Sonic Hedgehog (Shh) signaling and cilium length and morphology regulation (28).

1.3 Primary cilia and signal transduction

The complexity and evolutionary stability of the primary cilium suggest that it has some important functionality. For a long time, primary cilia was known for its role in Hedgehog signaling, making it indispensable for proper development. In mammalian cells, Shh receptor patched 1 (Ptch1) localizes to the primary cilium in absence of the ligand, and excludes the intermediate signaling molecule smoothened (Smo) from it. Protein kinase A (PKA) promotes proteolytic processing of Gli2/3 into a repressor form, thereby inhibiting Shh-driven gene expression. In the presence of Shh, Ptch1 translocates to the plasma membrane, and Smo moves into the cilium. This abrogates PKA activation, promoting Gli2/3 accumulation in the ciliary tip and activating Gli transcription factor formation (29-31).
Recently, several of the receptor tyrosine kinases (RTK) were reported to localize to the primary cilium, and signal in a cilium-dependent manner. Platelet-derived growth factor receptor (PDGFR) α was found to specifically accumulate in the primary cilium of fibroblasts, while PDGFRβ was excluded from the cilium. Engineered loss of the cilium induces rapid degradation of PDGFRα, and loss of its signaling ligand, PDGF-AA, while preserving signal transduction of PDGF-BB, a PDGFRβ-specific ligand (32). Insulin-like growth factor 1 receptor (IGF1R) is not exclusive to primary cilium, however, ciliary localization tends to sensitize it, as activation of the receptor upon stimulation was first detected in the cilium, and then spread further to the plasma membrane. Similarly to PDGFRα, loss of cilia drastically decreases ligand-induced activation of IGF1R and downstream phosphorylation of protein kinase B (AKT) (33). Other RTKs were also reported to localize to primary cilia, such as epidermal growth factor receptor (EGFR), which was found in cilia in kidney epithelial cells (34), astrocytes, and neuroblasts (35). Fibroblast growth factor receptor (FGFR) was reported to localize to motile cilia in the airways of rhesus monkeys (36), as well as to the basal body of primary cilia in mouse neural progenitor cells (37). Angiopoietin receptors Tie1/2 localize to primary cilia on the surface epithelium of the murine ovary, bursa, and extra-ovarian rete ducts (38). Unfortunately, the significance and role of cilia in these RTK signaling cascades are still unknown.

Finally, a long list of receptors from the superfamily of G-protein coupled receptors (GPCR) was found to accumulate in the primary cilium of various cell types (39, 40). Several cilium-targeting sequences were identified within different types of GPCRs (41, 42). Still, the importance of the cilium for GPCR signaling is very poorly understood. There is evidence suggesting that the cilium serves as a compartment to scaffold GPCR signaling components including adenylyl cyclases (AC) 3/5/6 and phosphodiesterase 4C, thus limiting the spread of downstream signaling (43). In addition to this, it has become evident that cilia can serve as a platform for GPCR signaling crosstalk through GPCR hetero-oligomerization (44) and downstream signaling modulation by co-localized receptors (45). In addition to these, a growing body of evidence indicates that the downstream effectors of GPCRs, heterotrimeric G-proteins, can also be accumulated or excluded from primary cilium. For example, Gαs is accumulated in cilia (46), as well as
Gα_{i2} and i3, while Gα_{i1} is excluded from it (47). Since GPCRs can usually interact with several types of Gα subunits, such compartmentalization creates a possibility for the cilium to act as a switch in GPCR signaling.

1.4 Primary cilia loss/dysfunction associated diseases

Mutations in ciliation-associated genes can cause a plethora of diseases, collectively referred to as ciliopathies. Ciliopathies are systemic diseases with a wide variety of symptoms, usually including the development of abnormalities (polydactyly, situs inversus), vision loss, cyst formation in multiple organs, obesity, and neurological disorders (48). A classic example of a ciliopathy is Joubert syndrome (JBTS; MIM#213300). It is characterized by hypotonia, ataxia, psychomotor delay, an irregular breathing pattern, and distinctive cerebellar and brain stem malformations. Additional clinical features include retinal degeneration, cystic kidney disease, ocular colobomas, occipital encephalocele, hepatic fibrosis, polydactyly, and endocrine abnormalities (49). Another classic example is Bardet-Biedl syndrome (BBS, MIM#209900), which includes rod-cone dystrophy, polydactyly, obesity, learning disabilities, hypogonadism, and renal anomalies. Secondary features include speech delay or disorder, developmental delay, behavioral abnormalities, brachydactyly/syndactyly, ataxia/poor coordination/imbalance, mild hypertonia, anosmia, diabetes, fibrocystic liver disease, Hirschsprung’s disease, as well as dental and cardiovascular anomalies (50). Symptoms and clinical representations of ciliopathies are largely overlapping, and can be separated by developmental abnormalities such as polydactyly and situs inversus, which are usually associated with impaired Shh signaling, or by degenerative processes, such as retinal degeneration, and different manifestations of dysplasia. The latter is of particular interest, as it occurs through the whole life of the patient and manifests as cyst formation in the kidney (51) and liver (52). Interestingly, modeling loss of cilia usually produces a hyperproliferative phenotype in normal cells (53, 54), thus one may expect to see increased incidence of cancer in patients with ciliopathies. Unfortunately, no such data is currently available, however Birt-Hogg-Dubé syndrome, which is associated with an increased incidence of renal cancer, was recently recognized as a ciliopathy (55).
2. Primary cilia: potential target for anti-cancer therapy

2.1 Primary cilia and cancer

In multiple cancer types, cilia tend to be lost, however, the role of this event is not clear. Recent publications suggest that loss of cilia in cancer is a relatively early event in disease progression. For instance, a drastic decrease in ciliation can be observed in breast cancer at the stage of non-invasive ductal carcinoma in situ (56). The same observation holds true in prostate cancer. In preinvasive stage of prostatic intraepithelial neoplasia, the number of cilia is significantly decreased (57). In a mouse model of pancreatic cancer, loss of cilia was noted even earlier in pre-cancer lesions. In this model, pancreatic intraepithelial neoplasia of varying grades can be detected prior to tumor development, and in these lesions, cilia were already absent (58). On the other hand, a few reports claim that cilia may be needed for cancer progression in some cases. Since Shh signaling requires the primary cilium, cancer development in models driven by the activation of Smo was strongly inhibited by loss of the cilia, but if the driver was the activated form of Gli, then the cilia loss enhanced tumorigenesis (59, 60). So far, such observations have only been specific for Shh-driven tumors, which puts them on a list of peculiar exceptions from the general trend.

So far, cilia loss seems to correlate with tumor progression and also perhaps, malignant transformation, but is it a driving force for the latter, or is it just a consequence of transformation? Modeling the loss of cilia in normal cells suggests that it promotes hyperproliferation in Shh-independent cells. Engineered loss of primary cilia promotes proliferation in the mouse dermis in vivo (54). In cell culture settings, deciliation of normal cholangiocytes was sufficient to increase the proliferation rate, and moreover, loss of cilia promoted attachment-independent growth (53). In the case of Shh-dependent cell populations such as neural stem cells, ablation of primary cilia seems to inhibit their proliferation and lead to hypocellularity (61, 62). This observation goes along with tumor models driven by Smo activation, where cilia are required for tumor initiation (59, 60).

Several approaches have been made to restore primary cilia in cancer cells. In cholangiarcinoma cells, depletion or inhibition of the protein HDAC6, which is
implicated in cilia disassembly (19), was found to robustly restore primary cilia and suppress proliferation (53). In glioblastoma cells, depletion of CCRK, which is also implicated in cilia disassembly, was found to significantly inhibit proliferation and restore ciliation. Interestingly, the number of ciliated cells increased up to 10% in this study, but depletion of protein KIF3A, which is required for cilia assembly, abrogated all effects of CCRK depletion on both ciliation and proliferation (27).

Overall, in the majority of cancers, loss of cilia seems to be an early event associated with an increase in proliferation, and restoration of the cilia, even in small cell populations, drastically decreases the proliferative capacity of cancer cells.

2.2 Glioblastoma and primary cilia

GBM is one of the most fast progressing cancers, which has a median patient survival of 13-16 months (63). Currently, treatment options for GBM are very limited, with the standard of care including aggressive surgical resection, radiation therapy, and chemotherapy (64). Unfortunately, due to its high invasiveness and fast tumor growth rate, the majority of GBM patients present signs of recurrent disease within 32-36 weeks (65). There is therefore a very critical need for the discovery of new targets and the design of new therapeutic approaches to treat GBM.

Recently, GBM was reported to have a drastically decreased ciliation rate. Only about 10% of GBM cells can assemble cilia. Moreover, electron microscopy analysis of GBM biopsies showed that the few cilia that they do form possess multiple structural abnormalities (66-68). Further inhibition of primary cilia assembly in patient-derived GBM primary cell culture through the introduction of a dominant-negative variant of KIF3A seems to have a minimal and non-coherent effect on both cell proliferation in vitro and tumor growth in a mouse intracranial model (69). On the other hand, even minimal restoration of primary cilia seems to have a tremendous effect on cell proliferation (27). This clearly suggests that loss of cilia in GBM is a non-random event and may be associated with the high proliferative capacity of tumor cells. Understanding the mechanisms of cilia loss in GBM and which pathways lead to increased proliferation upon loss of the cilia will allow to devise new strategies to battle GBM.
3. LPA signaling in mammalian cells

3.1 LPA production and function

LPA (lysophosphatidic acid) is a water-soluble lipid metabolite with a wide variety of cellular functions. LPA promotes proliferation in fibroblasts (70), astrocytes (71), and multiple other cell types (72-77). In addition to proliferation, LPA promotes cell migration (76, 77), platelet aggregation (78), smooth muscle contraction (79), and neurite retraction (80), making it a versatile signal molecule. LPA is present in large amounts in serum (81), saliva (82), brain (83), and tumor ascites (84). For a long time, the biosynthesis of LPA was a mystery, but it is now known that there are two main pathways to produce LPA: 1) autotaxin (ATX), a secreted lysophospholipase D enzyme, converts lysophosphatidylcholine (LPC) into LPA (85), and 2) phospholipase A can produce LPA from phosphatidic acid (86). During development, LPA signaling participates in wound healing (87), blood and lymphatic vessel formation (88), and brain development (89).

3.2 LPA receptors: expression and function

LPA signals through a family of GPCRs known as lysophosphatidic acid receptors 1-6 (LPAR1-6) (Fig.2). LPARs have distinctive expression patterns and functions. LPAR1 is expressed in the heart, brain, placenta, skeletal muscle, kidney, pancreas, spleen, prostate, testis, ovary, small intestine, and colon (90). LPAR1 can interact with the heterotrimeric G-protein family members Gαi/o, Gα12/13, and Gαq/11 (91), and promote cell proliferation, migration, survival, and cytoskeleton rearrangements. LPAR1 knockout in mice can cause a reduction in body weight, minor craniofacial deformities, and increased neonatal lethality due to decreased suckling behavior (92). LPAR2 is expressed in the embryonic brain, testis, leukocytes, prostate, spleen, thymus, and pancreas (93). Predicted interactors of LPAR2 include Gαi/o, Gα12/13, and Gαq/11 G-protein family members. Surprisingly, LPAR2 knockout in mice did not reveal any gross abnormalities (94). LPAR3 is broadly expressed, interacts with Gαi/o and Gαq/11 G-protein family members, and its knockout in mice does not cause any severe gross abnormalities, however, multiple reproductive defects were observed in LPAR3 -/- females (95). LPAR4 is distinct from LPAR1-3, being structurally close to P2Y purinergic receptors, and interacts with all four major classes of Gα proteins (91). Knockout of LPAR4 in mice
produces embryonic lethality caused by impaired vascular development (88). LPAR5 is also structurally similar to P2Y receptors, and interacts with Ga12/13 and Gaq/11 G-proteins. LPAR5-knockout mice display decreased nociception and behavioral abnormalities such as decreased anxiety, motivational changes, and reduced social exploration (96). LPAR6 is the most recently discovered R2Y type of LPA receptor, which interacts with Ga12/13 (97). Knockout of LPAR6 does not seem to cause any alterations in mice behavior or development, however, it does completely abrogate liver regeneration (98). So far, nothing is known about the regulation or subcellular localization of LPARs.

![Figure 2. Schematic of LPAR signaling.](image)

3.3 LPA/LPAR signaling in cancer

Recently, it became evident that LPA signaling is involved in cancer development and progression. ATX, the major enzyme involved in LPA production, is highly expressed in multiple cancer types including neuroblastoma, hepatocellular carcinoma, breast cancer, renal cancer, and GBM (99). LPA promotes migration in a variety of cancers including pancreatic (84), prostate (100), breast (101), and GBM (102), as well as promotes proliferation (75). Mechanistically, LPA can activate multiple pathways inducing proliferation, potentially in cell type specific manner. In head and neck squamous cell carcinoma, LPA stimulation causes transactivation of EGFR (74), while in colorectal
cancer LPA promotes β-catenin pathway activation (75). In ovarian cancer, LPAR1 requires Gα12 to sustain LPA-driven proliferation (72), and Gαq is required for normal intestinal epithelium proliferation (103). Depletion of LPAR2 significantly decreases colitis-associated colon cancer development, while LPA promotes it (104). In addition, the level of LPA can be used as a prognostic marker in ovarian and gastric cancers (105, 106). Surprisingly, inhibition of LPA signaling is still poorly investigated as a therapeutic strategy against cancer, however, several works indicate that inhibition of LPAR1 with Ki16425 is sufficient to abrogate metastasis formation in breast cancer (107, 108) and inhibition of ATX increases radiosensitivity in GBM (109).

4. Kinesin-13 family motors and their role in cancer

4.1 Kinesin motor superfamily in regulation of microtubule dynamics

The kinesin superfamily is a superfamily of motor proteins capable of moving along microtubules. Most kinesins target to the growing “+” end of microtubules, but there are several exceptions. The primary role of kinesins is believed to be the transport of different cargoes within the cell. The kinesin superfamily includes 16 families of proteins: kinesin-1-12 possess a conserved N-terminal motor domain and move towards the “+” end of the microtubules (110-112), kinesin-13 family members have a motor domain in the middle and tend to disassemble microtubule lattice (113), and kinesin-14 family members have a C-terminal motor domain and move toward the “-” end of microtubules (114). The kinesin-1, 2, and 3 families are involved in the trafficking of membrane-bound vesicles and organelles, while the kinesin-4, 5, 6, and 14 families function during mitosis and participate in spindle microtubule organization and chromosome tethering (115). The kinesin-8 and 13 families regulate microtubule dynamics by either inhibiting microtubule elongation or initiating disassembly. Kinesin-8 family members have increased processivity, promoting accumulation of the motors at the “+” end of long microtubules (116). At the “+” end, kinesin-8 family members can prevent the addition of new tubulin dimers to the lattice or can directly remove tubulin from microtubules; however, reports on the ability of kinesin-8 to directly disassemble microtubules are controversial (117). Kinesin-13 family members are directly implicated in microtubule disassembly. Their motor domain localizes in the middle of the protein, and by itself can destabilize
microtubules (118, 119), but their disassembly rate is significantly enhanced by the addition of the neck region, which directly precedes the motor domain (120-122). Mechanistically, kinesin-13 family members disassemble microtubules by bending tubulin protofilaments at the end of microtubules, locking them in an unstable conformation, and thus, initiating microtubule catastrophe (123, 124).

4.2 Cellular function of kinesin-13 family members

Kinesin-13 family members include KIF2A, KIF2B, KIF2C and KIF24 proteins (117). KIF2A is involved in mitosis and is required for bipolar spindle formation (125). It is also well known to be involved in brain development through suppression of axon branching and to be required for axon pruning (126, 127). It seems to be involved in the regulation of cytoskeleton remodeling during cell movement through interaction with Arf GAP using GTP-binding protein-like, ankyrin repeats and PH Domains1 (AGAP1), but the implications of this are still vague (128). KIF2B is poorly studied, but it is known to have a distinct function during mitosis (125). KIF2C is well known for its mitotic functions (125), and was shown to interact with EB1 and EB3 and target growing microtubules, suggesting potential participation in rapid tubulin cytoskeleton rearrangements (129). KIF24 participates in the remodeling of centriole microtubules (130) and suppresses cilium assembly during mitosis (131). KIF2A and KIF2C were recently shown to be able to induce cilia disassembly (23). Surprisingly, both studies involved KIF24 and KIF2A/C and did not distinguish between the effects of the kinesin-13 family members on pre-formed cilia versus de-novo ciliogenesis.

4.3 Kinesin-13 family members in cancer

Recently, the potential involvement of kinesin-13 family members in cancer was highlighted in multiple publications. For instance, all of the kinesin-13 family members are associated with progression and poor prognosis of hepatocellular carcinoma (132). High expression of KIF2A can predict poor prognosis for diffuse large B-cell lymphoma (133) and gastric cancer (134), and it is associated with high-grade glioma (135). KIF2C was found to have strong prognostic value in renal clear cell carcinoma (136) and glioma (137), and was recognized as a potential anti-cancer drug target (138). The reason for such a strong association with poor prognosis of kinesin-13 family motors, particularly
KIF2A and KIF2C, is still elusive. However, several lines of evidence indicate that KIF2A expression is required for maintaining a highly proliferative phenotype and supporting migration in cancer cells (135, 139). The same observations were made for KIF2C (140, 141). Moreover, depletion of KIF2A or KIF2C is sufficient to induce apoptosis in cancer cells (142) or to promote senescence (143). Interestingly, both KIF2A and KIF2C induce primary cilia disassembly (23), and even partial restoration of the primary cilia drastically inhibits cancer cell proliferation (27, 53). Thus it is tempting to speculate that KIF2A and KIF2C drive the loss of primary cilia in cancer cells.

5. **Aurora kinase A: master regulator of cilia**

5.1 **AURKA structure and function**

AURKA is a mitotic serine/threonine kinase. The Aurora family of proteins consists of three known members: AURKA, AURKB, and AURKC. The N-terminal domain (1-128aa) of AURKA targets it to the basal body/centrosomes and allows it to interact with microtubules during mitosis (144). The N-terminal domain also inhibits the catalytic activity of AURKA when it is not bound to activating proteins (145) such as NEDD9 and TPX2. Activation of AURKA results in autophosphorylation of threonine 288 (activational phosphorylation) (19, 146-148) and serine 51 (protecting from degradation) (149). Inactivation of AURKA is regulated by protein phosphatase type 2a (PP2a) (150). Active AURKA is targeted to the centrosome through microtubule binding where it can function as a mitotic kinase. During mitosis, AURKA regulates the formation of Cdk1/CyclinB1 complex through phosphorylation and activation of cdc25b phosphatase, which removes inhibitory phosphorylation from Cdk1 (151). Accumulation of AURKA is required for centrosome maturation and segregation (152). After nuclear envelope breakdown, AURKA is targeted to the mitotic spindle in complex with the microtubule-binding protein TPX2 (146). Depletion of AURKA in normal cells results in G2/M arrest or the formation of a monopolar spindle, causing an inability to separate DNA and subsequent cell death (153).

5.2 **Role of AURKA in regulation of the ciliary dynamics**

Most AURKA studies focus on its role in mitosis and G2/M AURKA activation. Recently, a non-mitotic role of AURKA as a master-regulator of cilia disassembly became
evident. Serum stimulation of G1/G0-synchronized cells yielded activation of AURKA that was spatially restricted to the centrioles, and also cilia disassembly. In these settings, disassembly of the cilia occurs in two waves: first, within 1-2 hours after serum stimulation, and second, after 18-24 hours. The latter represents G2/M transition, but the first wave occurs during G1. Inhibition or depletion of AURKA completely abrogates the disassembly of cilia, while injection of the cells with pre-activated AURKA induces rapid deciliation (19). The exact mechanism of AURKA activation during the initiation of cilium disassembly has yet to be elucidated. However, several proteins participating in this event have already been established. Loss of NEDD9, a phosphorylation-independent AURKA activator, severely blunted cilia disassembly in response to serum (19). Calmodulin was shown to directly activate AURKA in a Ca²⁺-dependent manner, and binding to calmodulin is a prerequisite for serum treatment-induced cilia disassembly (154). Pitchfork (Pifo) also interacts directly with AURKA and promotes AURKA activation during cilia disassembly (155).

Figure 3. Schematic of regulation of human KIF2C through phosphorylation.

5.3 AURKA and KIF2C interface in mitosis and cilia

KIF2A and KIF2C, microtubule-destabilizing kinesins, are potential candidates for direct disassembly of the cilia (23). During mitosis, AURKA regulates spindle targeting of both KIF2A and KIF2C, and interestingly, AURKA phosphorylation of KIF2A suppresses
its microtubule depolymerizing activity and suppresses spindle microtubules binding (25). KIF2C phosphorylation of serine 192 by AURKA can also suppress its depolymerization activity, however, the main effect of AURKA seems to be due to the phosphorylation of serine 719 (xenopus)/ 715 (human), leading to the redistribution of KIF2C to bipolar spindle microtubules (26). Plk1, a direct target of AURKA, can also phosphorylate serine 715 and enhance depolymerization activity of KIF2C (156). In non-mitotic ciliated cells, overexpression of KIF2A or KIF2C initiates disassembly of cilia, but KIF2A was more potent (23). The observations were made in a serum-free media synchronized cell population, where AURKA is mostly inactive. Taking previously discussed data into account, activation of AURKA may drastically change the picture, since it will tend to inhibit KIF2A and activate KIF2C (Fig.3).
References

42. Schou KB, Pedersen LB, Christensen ST. Ins and outs of GPCR signaling in primary cilia. EMBO reports. 2015;16(9):1099-113.
64. Adult Central Nervous System Tumors Treatment (PDQ(R)): Health Professional Version. PDQ Cancer Information Summaries. Bethesda (MD)2002.
120. Hertzer KM, Ems-McClung SC, Kline-Smith SL, Lipkin TG, Gilbert SP, Walczak CE. Full-length dimeric MCAK is a more efficient microtubule depolymerase than minimal domain monomeric MCAK. Molecular biology of the cell. 2006;17(2):700-10.


149. Littlepage LE, Ruderman JV. Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes & development. 2002;16(17):2274-85.
**Study1:** LPA signaling is regulated through the primary cilium: a novel target in glioblastoma.

Yuriy V. Loskutov¹, Caryn L. Griffin¹, Kristina M. Marinak¹, Andrey Bobko², Naira V. Margaryan², Werner J. Geldenhuys³, Jann N. Sarkaria⁵ and Elena N. Pugacheva¹,²,⁴

¹ WVU Cancer Institute, ² Department of Biochemistry, ³ Department of Pharmaceutical Sciences, Department of Radiation Oncology⁴ West Virginia University School of Medicine, Morgantown, WV, USA 26506. ⁵ Mayo Clinic, Rochester, MN, USA 55905

Accepted for publication in Oncogene on September 25th, 2017.

Corresponding author:

Elena N. Pugacheva,
Department of Biochemistry,
PO Box 9142, 1 Medical Center Drive,
West Virginia University School of Medicine,
Morgantown, WV 26506.
Phone: 304-293-5295
Fax: 304-293-4667
E-mail: epugacheva@hsc.wvu.edu
Abstract

The primary cilium is a ubiquitous organelle presented on most human cells. It is a crucial signaling hub for multiple pathways including growth factor and G-protein coupled receptors. Loss of primary cilia, observed in various cancers, has been shown to affect cell proliferation. Primary cilia formation is drastically decreased in glioblastoma (GBM), however, the role of cilia in normal astrocyte or glioblastoma proliferation has not been explored. Here we report that loss of primary cilia in human astrocytes stimulates growth rate in a lysophosphatidic acid (LPA)-dependent manner. We show that lysophosphatidic acid receptor 1 (LPAR1) is accumulated in primary cilia. LPAR1 signaling through Gα12/Gαq was previously reported to be responsible for cancer cell proliferation. We found that in ciliated cells, Gα12 and Gαq are excluded from the cilium, creating a barrier against unlimited proliferation, one of the hallmarks of cancer. Upon loss of primary cilia, LPAR1 redistributes to the plasma membrane with a concomitant increase in LPAR1 association with Gα12 and Gαq. Inhibition of LPA signaling with the small molecule compound Ki16425 in deciliated highly proliferative astrocytes or glioblastoma patient-derived cells/xenografts drastically suppresses their growth both in vitro and in vivo. Moreover, Ki16425 brain delivery via PEG-PLGA nanoparticles inhibited tumor progression in an intracranial glioblastoma PDX model. Overall, our findings establish a novel mechanism by which primary cilium restricts proliferation and indicate that loss of primary cilia is sufficient to increase mitogenic signaling, and is important for the maintenance of a highly proliferative phenotype. Clinical application of LPA inhibitors may prove beneficial to restrict glioblastoma growth and ensure local control of disease.
**Introduction**

The primary cilium is a ubiquitous, microtubule-based organelle which is built on top of a membrane-anchored basal body. Primary cilium is an important negative regulator of proliferation and a key sensory organelle. It serves as a hub for multiple signaling cascades including receptor tyrosine kinase (1), Sonic hedgehog (Shh) (2), and G-protein coupled receptors (GPCRs) (3). Disassembly of primary cilium leads to release of the basal body, also called the mother centriole, which is required for mitotic spindle formation and mitosis. Multiple mitotic kinases initiate cilium disassembly including AURKA, Plk1, and Nek2 (4-6). Centrosome sequestration is considered one of the primary mechanisms of negative regulation of proliferation by primary cilium. Nevertheless, cilium shortening and disassembly is often observed immediately after growth factor stimulation in interphase (4). The role of this short-term disassembly in cell proliferation is currently unknown. Recent publications suggest that in different types of cancer including breast, prostate, renal, and glioblastoma (GBM), cilia tend to be lost (7-10). However, the importance of this event on tumor maintenance and progression or treatment is not well understood.

Several studies report that loss of primary cilia in normal cells increases proliferation and supports attachment-independent growth (11, 12), which are common hallmarks of cancer. Attempts to restore primary cilia in cancer cells yield a significant inhibition on proliferation (12, 13). These observations suggest that cilia loss can promote/sustain a highly proliferative phenotype. However, in a subset of Sonic hedgehog (Shh)-dependent medulloblastomas, presence of cilium is mandatory (14) for cancer maintenance, therefore studies on specific cancer subtypes are warranted to establish cilia’s role in tumor biology and potential therapeutic applications.

Astrocytoma is the most commonly diagnosed adult brain cancer (15), which often progresses to GBM. The majority of GBM patients succumb to the disease within 13-16 months (15). GBM is a highly proliferative disease with limited treatment options (16). Lysophosphatidic acid (LPA) is an abundant mitogen in brain tissue (17). LPA acts through binding of heterotrimeric G-protein coupled receptors (LPA1-6). It was previously reported that LPAR1 can signal through Gαi, Gα12, and Gαq family members (18, 19). LPA stimulates cell proliferation in astrocytes (20) and cancer cells (21).
Astrocytes are abundant glial cells and well known for their ability to proliferate, especially in the activated state (22), and were previously reported as the potential cells of origin for GBM (23).

In our current work, we establish that loss of primary cilia promotes proliferation of primary non-transformed human astrocytes, providing permissive conditions for transformation in an LPA-dependent manner. GBM primary cells, with a decreased occurrence of primary cilia, were also sensitive to LPA and LPAR1/3 inhibition. Mechanistically, we found that LPA-LPAR1-driven mitogenic signaling was restricted in cells with primary cilium due to compartmentalization of LPAR1 and its downstream effectors, Gα12 and Gαq, in cilia and in cytoplasm, respectively. LPAR1 was redistributed to the plasma membrane upon loss of primary cilium, thus enabling its binding to Gα12 and Gαq, and therefore suggesting that redistribution of LPAR1 is a key mechanism driving proliferation in a cilia-dependent manner.

Inhibition of LPAR1/3 with the small molecule inhibitor Ki16425 significantly reduces cell growth rate only in deciliated astrocytes. Likewise, patient-derived GBM proliferation was stimulated by LPA and abrogated by Ki16425 in a dose-dependent manner. Importantly, the growth of GBM patient-derived xenografts in vivo was drastically decreased upon Ki16425 administration as a monotherapy without significant side effects.

Taken together, our findings indicate that loss of primary cilia eliminates spatial barriers curbing proliferation, thus unlocking the potential for unlimited proliferation. LPA is one of the key mitogenic factors driving highly proliferative GBM with no or very low basal ciliation, therefore clinical interventions based on inhibiting LPA signaling may significantly improve GBM patient survival and local disease control.
Results

Loss of primary cilium promotes proliferation of astrocytes.

Human astrocytes (HA) can form primary cilia. Incubation in serum-free media (SFM) promotes ciliation resulting in nearly 80% of cells having cilia (Fig.1A-B). This ciliation rate is similar to that observed in vivo (24). To allow for long term experiments, the primary human astrocytes (HA) were immortalized using SV40 large T antigen (HA-LTA) (25). Immortalization by LTA did not affect ciliation, which was similar to the parental astrocytes (Fig.S1A). To test how loss of primary cilia affects proliferation of primary (HA) or immortalized (HA-LTA) astrocytes, we utilized shRNA-driven knockdown of IFT88 or KIF3B, which are well characterized components of cilium assembly machinery (26, 27). Two shRNAs were used to target IFT88 or KIF3B resulting in up to a 90% knockdown (Fig1.C). Depletion of either IFT88 or KIF3B was sufficient to decrease ciliation to 5-15% (Fig.1D-E). These ciliation rates are similar to tissue biopsies from GBM patients (28).

The loss of primary cilia resulted in a significant increase in growth rate of both immortalized and primary astrocytes (Fig1.F-G). Interestingly, this difference in growth rate was observed between ciliated (shCon) and deciliated (shKIF3B or shIFT88) cells only upon addition of serum-supplemented media (SSM), but not in SFM. Addition of SSM caused resorption of primary cilia in control cells in a biphasic wave pattern (Fig.S1B), which has been described previously for other cell types (4). These findings indicate that loss of primary cilia by itself does not promote proliferation, but rather increases the response to some mitogenic stimuli present in serum.

Loss of primary cilia changes spatio-temporal response to mitogen stimulation.

To elucidate the potential mechanism underlying cilia-dependent changes in cell growth rate, a time course analysis of synchronized (SFM starved) astrocytes was performed. Phosphorylation of ERK1/2 (Thr202/Tyr204) and AKT (Ser473), common readouts for a variety of mitogen and pro-survival stimuli, was used to follow the serum-induced response. In agreement with previous reports, addition of 10% serum triggers a rapid (5-60min) increase in ERK1/2 and AKT phosphorylation followed by a gradual decrease (60-240min) in phosphorylation in all cell lines independent of ciliation status (Fig.2, Fig.3). Interestingly, the amount of phosphorylated ERK1/2 was twofold higher in
deciliated cells (shKIF3B or shIFT88) than in control (shCon) based on immunofluorescent and western blot assays (Fig.2A-F). Contrary to ERK1/2, phosphorylation of AKT was twofold lower in deciliated cells than in control (Fig.3A-F), indicating that changes in the pattern and intensity of the signal initiation/propagation act in a cilia-dependent manner.

Lysophosphatidic acid signaling is critical for increased proliferation in deciliated astrocytes.

To define the mitogene/s potentially responsible for the hyperproliferative phenotype of deciliated astrocytes, charcoal-stripped serum was used. Charcoal stripping is an efficient way to deplete bioactive lipids, as well as hormones and some vitamins (29), but preserve protein-based growth factors. Surprisingly, charcoal-treatment of serum (cSSM) was sufficient to completely abrogate the increase in growth rate observed in deciliated astrocytes (Fig.4A). One of the most abundant lipid-based mitogens found in serum is lysophosphatidic acid (LPA), which binds to LPA receptors (LPARs) to elicit a response. To test if LPA is involved in deciliation-dependent stimulation of proliferation, a small molecule inhibitor of LPAR1-3, Ki16425 (30), was used. Similar to cSSM, addition of Ki16425 to SSM was sufficient to abrogate the deciliation-dependent increase in growth rates, without any effect on growth of ciliated astrocytes (SSM vs. SSM+Ki16425) (Fig.4B). Moreover, addition of LPA alone to the serum-free medium (SFM) was sufficient to stimulate proliferation of astrocytes, and partially recapitulate the difference observed between ciliated and deciliated cells in the presence of serum (Fig.4B). As expected, LPA addition resulted in a pattern of ERK1/2 and AKT phosphorylation similar to the one observed during serum stimulation (Fig.4C-E). Surprisingly, treatment with EGF, bFGF, PDGF-A/B, or HGF as single agents was neither sufficient to induce proliferation (Fig.S2A) nor able to recapitulate the difference in phosphorylation of both ERK1/2 and AKT (Fig.S2B-C, Fig.S3A-B) previously observed between ciliated and deciliated cells (Fig.2E, Fig.3E). Interestingly, addition of a cocktail of protein growth factors (GFs) including EGF, bFGF, and B27 supplement along with LPA was sufficient to fully recapitulate the phenotype observed with addition of serum (Fig.4F). These findings indicate that LPA signaling is responsible for the highly proliferative phenotype observed
in astrocytes with disrupted ciliogenesis, but it requires additional growth factors to amplify its effect.

**LPAR1 localizes to primary cilia.**

To understand the mechanisms underlying cilia-dependent action of LPA, the subcellular localization of LPARs and Gα subunits participating in downstream signal transduction pathways was analyzed. A panel of LPARs fused with 3xFLAG-tag was exogenously expressed in astrocytes followed by immunofluorescent analysis using anti-FLAG antibodies. LPAR1 and LPAR3, but not LPAR6, were consistently localized in primary cilium (Fig.5A, S4A-B). Interestingly, in deciliated cells, both LPAR1 and LPAR3 were targeted to the plasma membrane (Fig.S5A-B). To exclude the possibility of overexpression-driven cilium targeting of LPAR1, we validated several anti-LPAR1 antibodies for immunofluorescent staining, using CRISPR-Cas9 driven LPAR1 depleted astrocytes as a control (Fig.S6). Utilizing validated antibodies we were able to confirm that endogenous LPAR1 localizes to primary cilium when it is present (Fig.S7).

Analysis of the cellular localization of multiple Gα subunits shows that only Gαs consistently targeted to primary cilia, similar to previous reports (31). However, whether other Gα subunits enter primary cilia is currently unknown. We found that Gαi1, Gαq, and Gα12 did not display ciliary localization, but rather diffuse cytoplasmic and plasma membrane staining (Fig.5C). Such a pattern of compartmentalization suggests that LPARs may engage in interactions with different Gα subunits depending upon presence or absence of primary cilia.

**LPAR1 directly binds to Gα12 and Gαq subunits in deciliated cells.**

To test this hypothesis, immunoprecipitation analysis was performed in shCon, shIFT88, and shKIF3B astrocytes transiently overexpressing 3xFLAG-LPAR1. Based on sequence similarity, LPAR1 is predicted to interact with Gαi, Gαq, and Gα12 (19). No interaction was detected between LPAR1 and Gαs. The robust co-immunoprecipitation of Gα12 and Gαq with LPAR1 was noted, being 2-3 times higher in deciliated astrocytes (Fig.5D). Previously, LPAR1 was reported to promote cancer cell proliferation specifically through Gα12 (18). Gαq was also reported to transmit pro-proliferative signals in cancer
We concluded that LPAR1 is sequestered in primary cilia, which prevents its interaction with cytoplasmic Gα_{12} and Gα_q, restricting its proliferative signaling. Loss of cilia promotes LPAR1 interaction with Gα_{12} and Gα_q, thus promoting the proliferative response to LPA (Fig. 5D).

**LPA signaling drives GBM proliferation both *in vitro* and *in vivo*.**

To evaluate our findings in disease-relevant settings, previously characterized GBM patient-derived cells and xenografts (33, 34) of two molecular subtypes (classical-GBM6 and mesenchymal-GBM12) were used. In agreement with previous reports (28), only 5-10% of GBM cells *in vivo* (GBM xenografts in mice, Fig. S8A-B) or *in vitro* (primary cells short term cultures, Fig. S8C-D) possess primary cilia. LPAR1 staining in GBM6 and 12 cells shows similar pattern to primary astrocytes (Fig. S8E). LPA was previously implicated in GBM progression and invasiveness (35), hence its effects on GBM cell proliferation was evaluated. Upon addition of LPA in serum-free GF-supplemented media, a significant increase of primary GBM cell growth rate *in vitro* was observed (Fig. S8F), while addition of the LPA inhibitor, Ki16425, to SSM decreases GBM cell growth rate in a dose-dependent manner (Fig. S8G).

Similar to *in vitro* studies, daily intraperitoneal administration of 30mg/kg Ki16425 as a monotherapy over 4-5 weeks significantly decreased the growth of subcutaneously transplanted GBM xenografts in immunodeficient mice (Fig. 6A-E). In agreement with *in vitro* PDX cell line proliferation data (Fig. S8G), the number of mitotic figures in Ki16425-treated tumors (Fig. 6D, E) was twofold lower. Overall, these findings indicate that LPA is an important mitogen in GBM and inhibition of LPA signaling is a viable option to improve anti-GBM therapy.

**PEG-PLGA Ki16425 loaded nanoparticles slow down GBM growth in brain.**

To assess the feasibility of targeting GBM with Ki16425 in patients, its effect on GBM growth was evaluated in an intracranial mouse model. Preliminary studies indicated that the regimen used for the subcutaneous GBM PDX experiment was not efficient in the intracranial model (Fig. S9A-B), suggesting that Ki16425 is not capable of crossing the blood brain barrier. To overcome this issue, we used a PEG-PLGA nanoparticle-based
delivery system (36) to allow for robust Ki16425 brain entry. Fluorescently labeled nanoparticles rapidly entered the brain upon IP injection and were gradually excreted/degraded over the next 12h period (Fig.S9C-D). To account for this decay, the regimen was modified to 30mg/kg Ki16425 loaded into nanoparticles and delivered every 12h. Mice were intracranially injected with 5x10⁵ GBM12 cells and tumor growth was monitored weekly via MRI. Upon tumors reaching 5mm³, mice were randomly assigned to Ki16425 or a vehicle loaded nanoparticles control group. Over 2 weeks of treatment, the Ki16425 nanoparticle-treated group showed a twofold decrease in tumor progression, compared to control (Fig.7A-B). In agreement with our previous experiments, the number of mitotic cells was decreased twofold (Fig.7C-D). These findings show that Ki16425 with a proper delivery method can significantly suppress GBM progression, and potentially, in combination with the current standard of care, improve local disease control and GBM patient survival.
**Discussion**

Primary cilium is well known for its role in multiple signaling cascades (1, 2, 11). Primary cilia length and the number of cells with cilia is significantly reduced or lost in multiple cancer types including GBM (7-10). Moreover, several studies have noted an increase in cell proliferation upon loss of primary cilia (11, 12). The proposed mechanism of cilia-driven proliferation control involves the sequestration of basal body (mother centriole) and the inability to form the mitotic spindle (37). Previously, it was shown that primary cilium disassembly is biphasic: a first wave of fast, transient disassembly within 1-2h after exposure to mitogenic stimuli (4), followed by a second wave of disassembly at 18-24h, which coincides with mitotic entry. The role of the first wave of cilium disassembly in mitogenic signaling is currently unknown, as is the mechanism/s underlying the increase in proliferation upon loss of primary cilia.

Several pro-proliferative signaling cascades are reported to require primary cilium for proper signal transduction. For instance, PDGF-AA signaling through PDGFRαα is lost in deciliated fibroblasts, therefore stimulation with PDGF-AA does not cause ERK1/2 or AKT activation (38); however, the overall proliferation effect of cilia loss was not evaluated in this work. SHH signaling is well-studied in conjunction with primary cilium. Loss of cilia ablates SHH signaling and Shh-driven proliferation (39), and correspondingly, Shh-driven cancers have a tendency to maintain high ciliation rates (14, 40). On the other hand, ciliary localization of IGF1R (41) and Notch (11) signaling is needed for differentiation and restriction of cell proliferation. Importantly, cilium can selectively sequester signaling components like GPR88 (42) and LPAR1/3 (Fig.5, S4) from their interaction with cilia-excluded co-factors, thus conferring selectivity on signal propagation/amplification through the lateral segregation of receptors. This strongly argues that the effect of primary cilia on proliferation is context-dependent, with pro-proliferative effects during development through Shh signaling and anti-proliferative effects in more differentiated cells.

In GBM, the complete inhibition of ciliogenesis seems to have minimal and non-coherent effects on overall proliferation and tumor progression (43). Nevertheless, ciliation compared to normal brain cells is drastically decreased (9), supporting an anti-mitogenic function of primary cilium in GBM. Our current findings suggest that the
engineered loss of primary cilia in normal human astrocytes phenotypically closely mimics transient cilium disassembly (Fig.S1B), and also resembles cilia loss in GBM cells (Fig.S8B, D). The increase in growth rate observed in deciliated cells (Fig.1F, G) suggests that transient cilia disassembly may be a key event augmenting mitogenic signaling. Mechanistically, we found that loss of primary cilia in human non-transformed astrocytes results in the amplification of ERK1/2 phosphorylation and promotes proliferation in an LPA-dependent manner (Fig.2, Fig.4). Interestingly, phosphorylation of AKT in response to LPA or serum stimulation was decreased in deciliated astrocytes (Fig.3). This can be attributed to inactivation of PDGFRαα (38) and IGF1R (41) driven signaling, and adds to the understanding of increased stress sensitivity in deciliated astrocytes (44). These findings support the idea that loss of primary cilia changes the pattern of the cellular response to mitogen stimulation, resulting in higher, more sustainable ERK1/2 activation thus explaining the increase in proliferation, but revealing the potential vulnerability of deciliated cells to stress via a decrease in pro-survival signaling (pAKT). Since GBMs usually have high pAKT levels (45) and we did not observe the transformation of deciliated astrocytes, we conclude that additional hit/s such as those well-known for GBM including RTK amplification/PTEN inactivation/PI3K activation, are required for overcoming the decrease in AKT activation.

Previously, LPA was implicated in the regulation of cell migration and proliferation (21, 35), however, the role of primary cilia in these signaling pathways was not explored. The LPA receptors (LPAR1/3) are specifically localized to primary cilium, but the LPAR downstream effectors, Gα12 and Gαq, are excluded from it (Fig.5, S4). Both Gα12 and Gαq activation is known to be implicated in cancer cell proliferation and cancer progression (46, 47). For Gα12, activation through LPAR1 specifically was reported in ovarian cancer cells (18). Our findings support the notion that in the absence of primary cilia, LPAR1 localizes to the plasma membrane and interacts with Gα12 and Gαq (Fig.5D, S5, S7). However, further research is required to pinpoint the intracellular compartment for Gα12 and Gαq and endogenous LPAR1 interaction. Hence, loss of primary cilia could be responsible for increased proliferation in a subset of cancers, and thus cilia restoration or the manipulation of cilia-dependent signaling such as LPA could be used to develop new therapeutic approaches to fight cancer.
GBM cells seem to be highly dependent on LPA as a mitogen, since inhibition of LPA signaling with Ki16425 abrogates their growth in vitro, and in both subcutaneous and intracranial GBM models (Fig.S8, Fig.6, Fig.7). Interestingly, the magnitude of the Ki16425 effect was the same between two in vivo models (Fig.6, Fig.7), suggesting that LPA signaling is equally engaged in both of them. LPA is known to be highly abundant in brain (3.7-35 pmol/mg) and serum concentration of LPA was reported to be close to this range (4-15.5 µM) (17). In addition, GBMs were reported to increase LPA production by secreting autotaxin (48). However, further studies are required for comprising the LPA levels in GBM PDXs grown in subcutaneous versus brain settings.

GBM6 and GBM12 used in the current study are of classical and mesenchymal molecular subtypes respectively, and are highly aggressive in mouse models (33, 34). Both of these subtypes are associated with rapid disease progression and poor prognosis. Our in vivo experiments clearly show that targeting LPA signaling yields a twofold reduction of tumor growth, specifically through a decrease in the proliferation rate of tumor cells (Fig.6, Fig.7). Moreover, utilizing a PEG-PLGA nanoparticles delivery system confirmed the effectiveness of targeting LPA signaling in intracranial settings. The median survival of GBM patients with the current standard of care including aggressive surgery, radiation, and chemotherapy (49) is about 12 months (15), with the majority of patients experiencing recurrence within 32-36 weeks (16). Targeting LPA signaling can prove to be highly beneficial in addition to standard care, since LPA is implicated in proliferation and migration/invasion (21, 35). Further studies are required, but based on our findings, we expect a substantial increase in recurrence-free survival upon inhibition of LPA signaling.

Overall, our data supports the role of LPA signaling in cancer cell proliferation, and for the first time, highlights primary cilia as a switch for the interpretation of LPA as a mitogen.
Materials and Methods

Cell lines and reagents

Human astrocytes isolated from human cortex (1800) were obtained from ScienCell Research Labs and maintained in DMEM/F12, supplemented with 10% heat-inactivated FBS, Antibiotic-Antimycotic (ThermoFisher) and 10 μg/ml of gentamycin (MP Biomedicals). Cells were propagated and cryopreserved at passage 2, for all studies cells were not passaged more than 10 times or 8 weeks, no authentication or mycoplasma testing were performed. For immortalization, primary astrocytes at passage 5 or 6 were cultured until 50–75% confluency and transfected with SV40 large T-antigen construct (25), followed by selection with 500μg/ml G418 (Sigma) until resistant colonies were formed. GBM6 and 12 PDXs (33) were kindly provided by Dr. Jann Sarkaria (Mayo Clinic, Rochester, MN) through a shared MTA agreement, no authentication or mycoplasma testing were performed. PDXs were maintained and used for intracranial injections or primary cell culture isolation as previously described (34). A list of antibodies and their used applications is outlined in Table S1. shRNA constructs were obtained from Dharmacron and are outlined in Table S2. All primers were purchased from IDT Technologies or Invitrogen, the sequences of which are reported in Table S3. The following reagents were used: Lysophosphatidic acid (LPA, Cayman Chemical), EGF and PDGF-AB (Sigma), HGF (R&D Technologies), bFGF (Peprotech), B27 supplement (ThermoFisher), Ki16425 (ApexBio). For lysophosphatidic acid stimulation experiments, bovine serum albumin (BSA; BP1600, Fisher Scientific) was used as a carrier and was added to all cells to a final concentration of 0.1%.

Western blotting

Western blotting was performed using standard procedures (50). Primary antibodies used are outlined in Table S1. Secondary anti-mouse and anti-rabbit HRP-conjugated antibodies (Jackson ImmunoResearch Labs) were diluted 1:10,000 followed by chemiluminescence-based detection with HyGLO™ (Denville Scientific). Bands were quantified using the digital electrophoresis documentation and image analysis software GeneTools (Syngene Corp.), with signal intensity normalized to either α-tubulin or GAPDH.
**Immunofluorescent cell analysis**

Cells were processed as previously described (4). Primary antibodies used are outlined in Table S1. Secondary antibodies included AlexaFluor 488, 555, and 647 (ThermoFisher). Images were captured using a standard setting by an LSM510 confocal microscope (Zeiss) (50). All images represent whole-cell 3D reconstructed projections with 0.4μm steps. All quantifications were done using ImageJ (NIH).

**Cell growth/proliferation analysis**

Cell growth rate was determined using semi-automated cell counting in ImageJ (NIH). Cells were plated at 1x10^4 cells per well and grown in the specified conditions for five days, fixed with methanol, and stained with Hoechst33342. Four random 10x fields per well were analyzed with at least three replicates per independent experiment; each graph represents at least three independent experiments.

**Fluorescent immunohistochemistry (F-IHC)**

Deparaffinization and rehydration of 4-5μm thin sections was performed as following: 1) three times for 3 min in xylene, 2) three times for 2 min in 100% ethanol, 3) 2 min in 95% ethanol, 4) 2 min in 80% ethanol, 5) 2 min in 70% ethanol, and 6) 5 min in 1XTBS. Antigen retrieval was done using 98°C citrate buffer, pH 6.0 for 20 minutes. Sections were blocked for 60 min with 5% BSA, 1XTBS solution and stained with the indicated primary antibodies. Secondary antibodies included AlexaFluor-488, 555, and 647 (ThermoFisher) and sections were mounted with ProLong Gold DAPI-containing media (ThermoFisher). Images were captured using LSM510 confocal microscope as previously described (50) (Zeiss). All images represent whole-cell 3D reconstructed projections with 0.4μm steps. All quantifications were done using ImageJ (NIH).

**LPAR cloning**

For robust expression and detection of LPARs, pcDNA3.1 vector was modified as previously described (51). Briefly, the insert containing the cleavable ER-targeting sequence followed by a 3xFLAG-tag and multiple cloning site (Table S3) was synthesized.
through String™ service (ThermoFisher) and cloned into pcDNA3.1 between HindIII and Sall restriction sites. LPAR1, 3, 6 cDNA was amplified from a Human Mammary Epithelial Cells (HMECs) cDNA library kindly provided by Dr. Alexey Ivanov (West Virginia University, Morgantown, WV); primers are shown in Table S3. The generated inserts were cloned into pcDNA3.1 ER-3xFLAG between BamHI and XhoI restriction sites. All constructs were validated by sequencing.

**Immunoprecipitation**

For LPAR1 immunoprecipitation, 3xFLAG-LPAR1 was transiently overexpressed in cells pre-incubated for 24h in serum-free media. Cells were lysed as previously described (52). 3xFLAG-LPAR1 was precipitated with anti-FLAG M2 affinity gel (Sigma) and used for subsequent Western blot analysis.

**Animal experiments**

NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) immunodeficient male mice (The Jackson Laboratory) were housed in the West Virginia University Animal Facility under pathogen-free conditions with an approved Institutional Animal Care and Use Committee protocol. For subcutaneous injections, 100µl of GBM6 or GBM12 tumor mash mixed 1:1 with Matrigel (Corning) was injected into the mice flanks. For intracranial injections, transient primary cell cultures were established as previously described (34), and 5x10⁵ cells in 5µl of Ca/Mg-free Dulbecco modified Phosphate Buffer Saline (DPBS) were administrated into the mouse cortex via stereotactic device-guided injection (34). Subcutaneous tumor growth was assessed weekly via caliper measurements; treatment was initiated upon tumor volume reaching 100mm³. Intracranial tumor volume was assessed weekly via contrast enhanced MRI (53) or twice a week via bioluminescence imaging (54); treatment was initiated upon tumor volume exceeding 5mm³. Animals were randomly assigned to the treatment group by simple randomization, investigator was single blinded during group allocation. Mice bearing subcutaneous tumors were intraperitoneally injected with 30mg/kg Ki16425 in 95% corn oil/5% DMSO or vehicle alone daily. For the intracranial model, mice were administered 30mg/kg Ki16425 loaded into PEG-PLGA nano-particles in PBS or given nano-particles alone twice daily. All animals were euthanized upon
reaching a moribund condition, according to the WVU IACUC Tumor Development and Tumor Scoring in Rodents policy.

**Contrast enhanced Magnetic Resonance Imaging (MRI)**
To visualize the intracranial tumors, mice were intraperitoneally injected with gadolinium-DTPA (contrast reagent, BioPAL) to a final concentration of 2mmol/kg (55), and imaged with a compact MRI system (ICON, Bruker). Images were taken with T1 weighted RARE sequence (echo time: 26.23ms; repetition time 1984.158ms; averages: 8; rare factor: 6). Overall time of scan was 25min and final resolution was 0.125mm for all axes. Stack images were reconstructed and analyzed using ImageJ (NIH).

**Animal bioluminescence imaging**
Mice were imaged twice a week for quantitative evaluation of tumor growth as previously described (56). Images were obtained using the IVIS Lumina-II Imaging System and Living Image-4.0 software (PerkinElmer).

**PEG-PLGA nano-particles**
Nano-particles were prepared as previously described (36). Briefly, PEG-PLGA and Ki16425 were dissolved in acetone and added dropwise into water. The nano-particles were stirred for 2 h at 40°C before being collected by centrifugation (4000g for 90 min). After discarding the supernatant, the nanoparticles were resuspended in Phosphate-Buffered Saline (PBS).

**Statistical analysis**
Statistical comparisons were made using two-tailed Student’s t-test. When more than two groups were analyzed, one-way or two-way analysis of variance (ANOVA) was used. P<0.05 was considered to be significant (*) as indicated in figure legends. All treatment groups were compared to vehicle/control unless mentioned otherwise. Experimental values were reported as the means with +/-S.E.M (standard error of mean). All calculations of statistical significance were made using GraphPad software. Sample sizes
and statistical analysis chosen were based on our previous experience and recommendations of biostatistician (4, 50, 56).
Conflicts of interest.
The authors declare no conflicts of interest.

Acknowledgments.
The authors thank Dr. Alexey Ivanov for sharing of the HMLE cDNA library and Brandon Jones for invaluable help with manuscript preparation.
References

44. Yoshimura K, Kawate T, Takeda S. Signaling through the primary cilium affects glial cell survival under a stressed environment. Glia. 2011;59(2):333-44.
55. Portnoy S, Bishop J, Dazai J, Spring S, Henkelman R. Characterization of signal enhancement following the intraperitoneal injection of Gadolinium based contrast agents.
**Figure Legends**

**Fig. 1. Loss of primary cilia promotes astrocyte proliferation in a growth factor-dependent manner.**

(A) Representative image of the cilium formed by primary human astrocyte (HA), stained for acetylated α-tubulin (AcTub, cilium marker) and γ-tubulin (γTub, basal body marker); scale bar – 10μm. (B) Quantification of primary astrocytes forming cilium, as in (A), in regular serum-supplemented media (SSM) or upon 48h of serum starvation (SFM); 300 cells, 100 cells in each of 3 independent experiments; Student’s t-test, p<0.05. (C) Western blot of IFT88 and KIF3B in primary and immortalized astrocytes (HA-LTA) stably expressing non-targeting shRNA (Con) or shRNA against IFT88 or KIF3B. (D, E) Quantification of primary astrocytes (D) and immortalized astrocytes (E) forming primary cilium, as in (B) upon depletion of IFT88 or KIF3B, as in (C); 300 cells, 100 cells in each of 3 independent experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05. (F, G) Growth rates of primary astrocytes (F) and immortalized astrocytes (G) upon depletion of IFT88 or KIF3B in full media or in serum-free conditions (SFM); 3 independent experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05.

**Fig. 2. Loss of cilium promotes increased ERK1/2 phosphorylation in response to serum stimulation.**

(A) Experiment schematics (top) and representative images of cells stably expressing non-targeting shRNA (Con) or shRNA against IFT88 or KIF3B, stained for acetylated α-tubulin (AcTub, cilium marker), γ-tubulin (γTub, basal body marker), and ERK1/2 phosphor-T202/Y204 (pERK1/2); scale bar – 10μm. (B, C, D) Quantifications of ERK1/2 phosphor-T202/Y204 intensities in whole cells (B), nuclei (C) and cytoplasm (D) as in (A); 100 cells in 3 independent experiments; two-way ANOVA with Dunnett’s post hoc test, p<0.05. (E) Representative western blot analysis of cells as in (A), stained for ERK1/2 phosphor-T202/Y204, total ERK1/2, and GAPDH. (F) Quantifications of ERK1/2 phosphor-T202/Y204 bands intensities, as in (E).

**Fig. 3. Loss of cilium promotes decreased AKT phosphorylation in response to serum stimulation.**
(A) Experiment schematics (top) and representative images of cells stably expressing non-targeting shRNA (Con) or shRNA against IFT88 or KIF3B, stained for acetylated α-tubulin (AcTub), γ-tubulin (γTub), and AKT phosphor-S473 (pAKT); scale bar – 10μm. (B, C, D) Quantifications of AKT phosphor-S473 intensities in whole cells (B), nuclei (C) and cytoplasm (D) as in (A); 100 cells in 3 independent experiments; two-way ANOVA with Dunnett’s post hoc test, p<0.05. (E) Representative western blot analysis of cells as in (A), stained for AKT phosphor-S473, total AKT, and GAPDH. (F) Quantifications of AKT phosphor-S473 bands intensities, as in (E).

Fig. 4. Lysophosphatidic acid promotes proliferation in deciliated astrocytes.

(A) Growth rates of immortalized astrocytes stably expressing non-targeting shRNA (Con) or shRNA against IFT88 or KIF3B in serum-supplemented media (SSM), media supplemented with charcoal-stripped serum (cSSM), or in serum-free conditions (SFM); 3 independent experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05. (B) Growth rates of cells as in (A) in serum-supplemented media (SSM), serum-supplemented media supplemented with 10μmol/L Ki16425, serum-free media supplemented with 1μmol/L LPA (SFM LPA), or in serum-free conditions (SFM); 3 independent experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05. (C) Experiment schematics (top) and representative western blot analysis of cells as in (A) stained for ERK1/2 phosphor-T202/Y204, total ERK1/2, AKT phosphor-S473, total AKT, and α-tubulin. (D) Quantifications of ERK1/2 phosphor-T202/Y204 bands intensities, as in (C). (E) Quantifications of AKT phosphor-S473 bands intensities, as in (C). (F) Growth rates of cells as in (A) SSM, SFM supplemented with 20ng/ml EGF, 20ng/ml bFGF, and B27 supplement (SFM-GF), SFM supplemented with 20ng/ml EGF, 20ng/ml bFGF, B27 supplement and 1μmol/L LPA (SFM-GF LPA), or in serum-free conditions (SFM); 3 independent experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05.

Fig. 5. Intracellular localization of LPA signaling cascade components.

(A) Representative images of immortalized astrocytes expressing exogenous 3xFLAG-LPAR1/LPAR3/LPAR6, stained for acetylated α-tubulin (AcTub, cilium marker), γ-tubulin (γTub, basal body marker) and FLAG-tag, arrowheads indicate primary cilium;
scale bar – 10μm (B) Representative images of immortalized astrocytes stained for acetylated α-tubulin (AcTub), γ-tubulin (γTub), Gαs, Gαq, Gα12 and Gαi1, arrowheads indicate primary cilium; scale bar – 10μm. (C) Immunoprecipitation of 3xFLAG tagged LPAR1 expressed in immortalized astrocytes stably expressing non-targeting shRNA (Con) or shRNA against IFT88 or KIF3B in serum-free conditions. (D) Schematic of potential mechanism of primary cilium restrictive action on the proliferative component of LPA signaling.

**Fig. 6. Inhibition of LPA signaling suppresses proliferation of GBM PDXs in vivo.**

(A) Representative images of mice subcutaneously injected with GBM6 (left panel) and GBM12 (right panel) and administered with vehicle or 30mg/kg/day Ki16425. (B, C) Analysis of tumor growth as in (A) for GBM6 (B) and GBM12 (C); 5 mice per group; two-way ANOVA with Sidak’s post hoc test, p<0.05. (D, E) Analysis of GBM6 (D) and GBM12 (E) terminal tumor weight; 5 tumors per group; Student’s t-test, p<0.05. (F, G) Representative images of GBM6 (F) and GBM12 (G), stained with DAPI; arrowheads indicate mitotic cells; scale bar – 20μm. (H, I) Quantification of mitotic figures as in (F, G) for GBM6 (H) and GBM12 (I); at least 1000 cells within 10 random fields per group; Student’s t-test, p<0.05.

**Fig. 7. Targeted brain delivery of Ki16425 suppresses GBM PDX growth in an intracranial model.**

(A) Representative MRI images of mice bearing intracranially grafted GBM12 throughout the treatment with PEG-PLGA nanoparticles loaded with Ki16425 (30mg/kg twice a day); scale bar – 5mm. (B) Analysis of tumor growth as in (A); 5 mice per group; two-way ANOVA with Sidak’s post hoc test, p<0.05. (C) Quantification of mitotic figures as in (D); at least 1000 cells within 10 random fields per group; Student’s t-test, p<0.05. (D) Representative images of tumors from (A), stained with DAPI; arrowheads indicate mitotic cells; scale bar – 20μm.
Figure 1. Loskutov
Figure 4. Loskutov
Figure 5. Loskutov
Figure 7. Loskutov
Supplementary Materials and Methods.

Generation of CRISPR-Cas9 driven LPAR1 knock out in astrocytes.

sgRNA targeting LPAR1 were designed using Broad institute web tool: https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design; synthesized as separate oligo nucleotides and cloned into pLentiCRISPR v2 (1) (a gift from Feng Zhang (Addgene plasmid # 52961)). Lentiviral particles were produced as previously described (2). Immortalized astrocytes were infected and selected on 1 µg/ml of puromycin until stable clones were formed. Individual cloned were established and tested for LPAR1 expression.

**Primary cilia formation in human astrocytes and astrocytes immortalized with large T antigen.**

**A.** Quantification of primary cilia in human astrocytes and human astrocytes immortalized with large T antigen (LTA) in serum-free media (SFM) as in Fig. 1 A-B; two-tailed Student’s t-test, n=3, 100 cells per experiment. **B.** Quantification of primary cilia over time in HA-LTA constitutively expressing shCon, shIFT88 or shKIF3B, pre-incubated for 48h with serum-free media (SFM) and stimulated with serum-supplemented media (SSM); experimental design on top, n = 3, per time point.

Supplementary Figure 1. Loskutov
Proliferation and ERK1/2 and AKT phosphorylation in response to single growth factor stimulation of HA-LTA.

A. Growth rate of HA-LTA with intact (shCon) or impaired (shIFT88, shKIF3B) cilogenesis in serum-supplemented media (SSM), serum-free media (SFM) or SFM supplemented with indicated single growth factors. One-way ANOVA with Dunnett's post hoc test, *p< 0.05; n=3. B, C. Representative western blot of response to single growth factor stimulation for cells as in A. Experimental set up shown in top B: serum-starved cells were treated with 20ng/ml of EGF (bottom B), 20ng/ml of bFGF (C), lysed in time-dependent manner; and stained with antibodies against Thr202/Tyr204 phosphorylated ERK1/2 (pERK1/2 T202/204), total ERK1/2, Ser473 phosphorylated AKT (pAKT S473), total AKT and GAPDH, as a loading control. * indicates bleed-through of pERK1/2 signal.
Proliferation and ERK1/2 and AKT phosphorylation in response to single growth factor stimulation of HA-LTA.

**A, B.** Representative western blot of response to single growth factor stimulation for cells as in Fig.S2A. Experimental set up shown in top Fig.S2B: serum-starved cells were treated with 10ng/ml of PDGF-AB (A), or 20ng/ml of HGF (B), lysed in time-dependent manner; and stained with antibodies against Thr202/Tyr204 phosphorylated ERK1/2 (pERK1/2 T202/204), total ERK1/2, Ser473 phosphorylated AKT (pAKT S473), total AKT and GAPDH, as a loading control. * indicates bleed-through of pERK1/2 signal.

Supplementary Figure 3. Loskutov
LPAR1, 3 and 6 subcellular localization in cells with assembled primary cilia.

A. Representative images of cells with primary cilia expressing 3xFLAG LPAR3 and LPAR6, stained for FLAG-tag, acetylated α-tubulin (AcTub, cilia marker) and γ-tubulin (γTub, centriole/basal body marker). Scale bar - 10μm. B. Signal intensity profile of the primary cillum and cell edge regions of cell in A and Fig.5A, as shown in pictogram on top.

Supplementary Figure 4. Loskutov
LPAR1, 3 and 6 subcellular localization in cells with disassembled primary cilium.
A. Representative images of cells w/o primary cilia expressing 3xFLAG tagged LPAR1, LPAR3 and LPAR6, stained for FLAG-tag, acetylated α-tubulin (AcTub, cilia marker) and γ-tubulin (γTub, centriole/basal body marker). Scale bar - 10μm. B. Signal intensity profile of the centriole and cell edge regions of cell in A, as shown in pictogram on top.

Supplementary Figure 5. Loskutov
**LPAR1 antibodies validation for immunofluorescent staining.**

A. Western blot of CRISPR-Cas9 induced knockout of LPAR1 in immortalized astrocytes (HA-LTA) stably expressing sgRNA (Con) or sgRNA against LPAR1. * indicates glycosylated forms of LPAR1. B-C. Representative image of HA-LTA, stained for acetylated α-tubulin (AcTub, cillum marker; B) or Arf13b (cilium marker; C), γ-tubulin (γTub, basal body marker) and LPAR1 (B - Proteintech 20442-1-AP, C - SantaCruz sc-615665); scale bar = 10μm.

Supplementary Figure 6. Loskutov
Endogenous LPAR1 localization in cells with and without primary cilium.

A. Representative images of HA-LTA with intact (shCon) or impaired (shIFT88, shKIF3B), stained for LPAR1, acetylated α-tubulin (AcTub, cilia marker) and γ-tubulin (γTub, centriole/basal body marker). Scale bar - 10μm. B. Signal intensity profile of the cillum/centriole and cell edge regions of cells in A, as shown in pictogram on top.
GBM6 and GBM12 have decreased ciliation and utilize LPA as a growth factor.
A. Representative images of GBM6 and GBM12 PDXs stained for Arl13b (marker of cilia) and γ-tubulin (γTub, marker of centriole/basal body). Arrows indicate primary cilia, black asterisks - ciliated cells, white asterisks - deciliated cells. Scale bar - 10 μm. B. Quantification of primary cilia occurrence in GBM6 and GBM12 xenografts as in A; n=3, 100 cells per group. C. Representative images of GBM6 and GBM12 cultured primary cells stained for acetylated α-tubulin (AcTub, marker of cilia) and γ-tubulin (γTub, marker of centriole/basal body). Arrows indicate primary cilia. Scale bar - 10 μm. D. Quantification of primary cilia occurrence in GBM6 and GBM12 primary cells, as in C; n=3, 100 cells per group. E. Representative images of GBM6 and GBM12 cultured primary cells stained for acetylated α-tubulin (AcTub, marker of cilia), LPAR1 and γ-tubulin (γTub, marker of centriole/basal body). Arrows indicate primary cilia. Scale bar - 10 μm. F. Growth rate of GBM6 and GBM12 primary cells in serum-free media supplemented with 20 ng/ml of EGF, 20 ng/ml of bFGF, B27 supplement and indicated concentrations of LPA. One-way ANOVA with Dunnett's post hoc test; #p<0.05 for GBM6 and GBM12 respectively, compared to no LPA control; n=3. G. Growth rate of GBM6 and GBM12 primary cells in serum-free media supplemented with 0.05 μmol/L of K11425 and indicated concentrations of K11425. One-way ANOVA with Dunnett's post hoc test; *p<0.05 for GBM6 and GBM12 respectively, compared to no K11425 control; n=3.
Administeration of Ki16425 has no effect on intracranial tumor growth.
A. Representative images of GBM12 growing in brains of mice treated with Vehicle-control or Ki16425. B. Quantification of bioluminescence, as in A; two-way ANOVA, Tukey post hoc test; n = 5. C. Representative images of mice brains injected with PEG-PLGA nanoparticles loaded with fluorescent dye. D. Quantification of fluorescence from brains as in C; n=2.

Supplementary Figure 9. Loskutov
<table>
<thead>
<tr>
<th>target</th>
<th>cat.#</th>
<th>host species</th>
<th>company</th>
<th>application</th>
<th>dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>acetylated alpha tubulin</td>
<td>T6793</td>
<td>mouse</td>
<td>Sigma</td>
<td>IF, F-IHC</td>
<td>1:1000</td>
</tr>
<tr>
<td>acetylated alpha tubulin</td>
<td>5335S</td>
<td>rabbit</td>
<td>Cell Signaling</td>
<td>IF</td>
<td>1:500</td>
</tr>
<tr>
<td>gamma tubulin</td>
<td>sc-7396</td>
<td>goat</td>
<td>Santa Cruz</td>
<td>IF, F-IHC</td>
<td>1:500</td>
</tr>
<tr>
<td>IFT88</td>
<td>60227-1-lg</td>
<td>mouse</td>
<td>Proteintech</td>
<td>WB</td>
<td>1:1000</td>
</tr>
<tr>
<td>Kif3B</td>
<td>sc-50456</td>
<td>rabbit</td>
<td>Santa Cruz</td>
<td>WB</td>
<td>1:500</td>
</tr>
<tr>
<td>alpha tubulin</td>
<td>16199</td>
<td>mouse</td>
<td>Sigma</td>
<td>WB</td>
<td>1:400000</td>
</tr>
<tr>
<td>pERK1/2 T202/204</td>
<td>9101</td>
<td>rabbit</td>
<td>Cell Signaling</td>
<td>IF, WB</td>
<td>1:200, 1:1000</td>
</tr>
<tr>
<td>ERK1/2</td>
<td>4695</td>
<td>rabbit</td>
<td>Cell Signaling</td>
<td>WB</td>
<td>1:1000</td>
</tr>
<tr>
<td>GAPDH</td>
<td>MAB374</td>
<td>mouse</td>
<td>Millipore</td>
<td>WB</td>
<td>1:800000</td>
</tr>
<tr>
<td>pAKT S473</td>
<td>AF887</td>
<td>rabbit</td>
<td>R&amp;D Systems</td>
<td>IF, WB</td>
<td>1:100, 1:500</td>
</tr>
<tr>
<td>AKT</td>
<td>2920</td>
<td>mouse</td>
<td>Cell Signaling</td>
<td>WB</td>
<td>1:1000</td>
</tr>
<tr>
<td>FLAG</td>
<td>F1804</td>
<td>mouse</td>
<td>Sigma</td>
<td>IF, WB</td>
<td>1:500, 1:1000</td>
</tr>
<tr>
<td>FLAG</td>
<td>PA1-984B</td>
<td>rabbit</td>
<td>Thermo Fisher Scientific</td>
<td>IF, WB</td>
<td>1:500, 1:1000</td>
</tr>
<tr>
<td>G alpha s</td>
<td>sc-135914</td>
<td>mouse</td>
<td>Santa Cruz</td>
<td>IF, WB</td>
<td>1:100, 1:500</td>
</tr>
<tr>
<td>G alpha q</td>
<td>sc-393</td>
<td>rabbit</td>
<td>Santa Cruz</td>
<td>IF, WB</td>
<td>1:200, 1:1000</td>
</tr>
<tr>
<td>G alpha 12</td>
<td>sc-409</td>
<td>rabbit</td>
<td>Santa Cruz</td>
<td>IF, WB</td>
<td>1:100, 1:200</td>
</tr>
<tr>
<td>G alpha i1</td>
<td>sc-391</td>
<td>rabbit</td>
<td>Santa Cruz</td>
<td>IF, WB</td>
<td>1:100, 1:500</td>
</tr>
<tr>
<td>Arl13b</td>
<td>17711-1-AP</td>
<td>rabbit</td>
<td>Proteintech</td>
<td>IF, F-IHC</td>
<td>1:400, 1:200</td>
</tr>
<tr>
<td>LPAR1</td>
<td>20442-1-AP</td>
<td>rabbit</td>
<td>Proteintech</td>
<td>IF</td>
<td>1:100</td>
</tr>
<tr>
<td>LPAR1</td>
<td>10005280</td>
<td>rabbit</td>
<td>Cyman chemicals</td>
<td>WB</td>
<td>1:250</td>
</tr>
<tr>
<td>LPAR1</td>
<td>sc-515665</td>
<td>mouse</td>
<td>Santa Cruz</td>
<td>IF</td>
<td>1:100</td>
</tr>
</tbody>
</table>

Supplementary table 1
<table>
<thead>
<tr>
<th>name</th>
<th>clone ID</th>
<th>targeting sequence</th>
<th>vector</th>
<th>company</th>
</tr>
</thead>
<tbody>
<tr>
<td>shlFT88#1</td>
<td>V3LHS_338157</td>
<td>GGAATAACA CACTGACCACCT</td>
<td>pGIPZ</td>
<td>Dharmacon</td>
</tr>
<tr>
<td>shlFT88#2</td>
<td>V3LHS_338155</td>
<td>AGCATCTGAATACTGACCA</td>
<td>pGIPZ</td>
<td>Dharmacon</td>
</tr>
<tr>
<td>shKif3B#1</td>
<td>V3LHS_644788</td>
<td>TTGCTAGTC TCTTCTCTCTCA</td>
<td>pGIPZ</td>
<td>Dharmacon</td>
</tr>
<tr>
<td>shKif3B#2</td>
<td>V3LHS_635533</td>
<td>ATCTCATTTCATCCTGCA</td>
<td>pGIPZ</td>
<td>Dharmacon</td>
</tr>
</tbody>
</table>

Supplementary table 2
<table>
<thead>
<tr>
<th>name</th>
<th>sequence</th>
<th>company</th>
</tr>
</thead>
<tbody>
<tr>
<td>BamHI-LPAR1</td>
<td>ATTGGATCCATGGCTGCCATCTCTACTTCC</td>
<td>IDT Technologies</td>
</tr>
<tr>
<td>LPAR1-TGA-XhoI</td>
<td>ATTCTCGAGTCAAACCACAGAGTGGTATTGCC</td>
<td>Invitrogen</td>
</tr>
<tr>
<td>BamHI-LPAR3</td>
<td>ATTGGATCCATGAATGAGTGTCACTATGACAAGC</td>
<td>IDT Technologies</td>
</tr>
<tr>
<td>LPAR3-TGA-XhoI</td>
<td>ATTCTCGAGTCAAACCACAGAGTGGTATTGCC</td>
<td>Invitrogen</td>
</tr>
<tr>
<td>BamHI-LPAR6</td>
<td>ATTGGATCCATGGTAAGCGTTAACAGCTCC</td>
<td>IDT Technologies</td>
</tr>
<tr>
<td>LPAR6-TGA-XhoI</td>
<td>ATTCTCGAGTCAAACCACAGAGTGGTATTGCC</td>
<td>Invitrogen</td>
</tr>
<tr>
<td>ER-3xFlag-MCS</td>
<td>GATCCTAAGCTTACCCGGTGATGAAAGACGATCGATCGCCCTGAGCTACATTTCTGGTTATCGCCATAGCTGAGTGAATTAAAGATCATGACATCGATTACAAAGGATGAGCGTACCTGTACAGCTAGCGAATTCTGCAGATATCGGCGCGCCGTCTTAAACACGCCTTCGAGTGATTAAATTAAGGTCGACGATCCT</td>
<td>Invitrogen</td>
</tr>
<tr>
<td>sgLPAR1_F</td>
<td>caccgTCTTTGGCTATGTTGCGCCAG</td>
<td>Invitrogen</td>
</tr>
<tr>
<td>sgLPAR1_R</td>
<td>aaacCTGGCGAACATAGCCAAAGAc</td>
<td>Invitrogen</td>
</tr>
</tbody>
</table>

Supplementary table 3
Study 2: The role of KIF2C/AURKA signaling in cilia loss and progression of glioblastoma.

Yuriy V. Loskutov, Joshua Arnold, Sila Yanardag, Werner J. Geldenhuys and Elena N. Pugacheva
Abstract

The primary cilium is a ubiquitous organelle presented on most human cells. It serves as a crucial signaling hub for multiple pathways including growth factor and G-protein coupled receptors. Loss of primary cilia was observed in various cancers, however, the implications of this event are unclear. Our long-term goal is to delineate the molecular mechanism of primary cilia disassembly under normal and pathological conditions and determine if the loss of the cilium is required for cancer progression. Aurora kinase A, a common proto-oncogene often overexpressed in GBM, initiates rapid cilia disassembly, but the downstream effectors of this pathway still have not been found. One of the potential AURKA effectors is the motor protein KIF2C, known to directly destabilize microtubules. AURKA can phosphorylate KIF2C on multiple sites during mitosis, however, nothing is known about AURKA and KIF2C interaction in non-mitotic cells. We found that KIF2C overexpression is triggering cilia disassembly in AURKA dependent manner, and are focusing on elucidating the molecular mechanism of the KIF2C driven cilia disassembly. Phosphorylation of KIF2C on S715 by AURKA was reported to enhance spindle pole microtubule targeting. Both spindle pole and axonemal microtubules are highly post-translationally modified, thus our central hypothesis is that AURKA-dependent phosphorylation of KIF2C on S715 leads to increased affinity towards post-translationally modified microtubules (acetylated and/or detyrosinated), and cilia disassembly, resulting in increase in cell proliferation and tumor progression.
Introduction

Glioblastoma multiforme (GBM) is one of the most deadly cancers for which no effective treatment strategy currently exists. The primary cilium is a ubiquitous microtubule-based organelle that protrudes from the apical surface of most human cells serving as a cellular antenna for signal transduction and is an important regulator of mitosis. Cilia are lost in many types of cancer including GBM (1-6). The importance of cilia loss for cancer progression is largely unknown, although several attempts to rescue ciliation in cancer cells reveal the therapeutic benefit behind primary cilia restoration (7, 8). The long-term goal of this study is to delineate the molecular mechanism of primary cilia disassembly under normal and pathological conditions and determine if the loss of cillum is required for cancer progression. This knowledge is critical for the development of new therapeutic strategies to prevent and eradicate tumor growth. Aurora kinase A (AURKA or AurA), a common proto-oncogene that is often overexpressed in GBM (9-12), initiates rapid cilia disassembly (7, 13), but the downstream effectors of this pathway have still not been found. One potential AURKA effector is the motor protein KIF2C, known to directly destabilize microtubules. KIF2C and its family member KIF2A were shown to promote cillum disassembly upon overexpression (14). KIF2C is phosphorylated by AURKA, which promotes its localization to highly post-translationally-modified spindle pole microtubules (15). Axonemal microtubules bear similar post-translational modifications as spindle pole microtubules and are usually detyrosinated (16). Interestingly, KIF2C has decreased activity towards detyrosinated microtubules (17), thus, the central hypothesis of this study is that AURKA-dependent phosphorylation of KIF2C leads to a change in substrate preference and cilia disassembly, resulting in an increase in cell proliferation and tumor progression. Rescue of ciliation will inhibit proliferation, disease progression, and also potentially, recurrence. This hypothesis was tested through the execution of the following aims:

Aim #1: Determine the mechanism/s of KIF2C-driven deciliation. The working hypothesis is that AURKA phosphorylation promotes KIF2C translocation from the cytoplasm to the primary cilium, where it orchestrates the disassembly of axonemal microtubules.
Aim #2: Determine the therapeutic benefits of combination therapy of KIF2C depletion and AURKA inhibition in the treatment of glioblastoma in patient-derived xenograft (PDX) models. The hypothesis is that the combination of KIF2C depletion and inhibition of AURKA will synergistically increase the incidence of primary cilia in cancer cells, as well as decrease tumor growth and potentially, recurrence. The rationale for the proposed work is that it will elucidate new mechanisms driving cilia disassembly, provide insight into the critical role of the primary cilia in cancer progression, and reveal new strategies for a targeted treatment of cancer.
Materials and methods

Cell lines and reagents

Human astrocytes isolated from human cortex (1800) were obtained from ScienCell Research Labs and maintained in DMEM/F12 supplemented with 10% heat-inactivated FBS, Antibiotic-Antimycotic (ThermoFisher), and 10 μg/ml of gentamycin (MP Biomedicals). Cells were propagated and cryopreserved at passage 2; for all studies, cells were not passaged more than 10 times or 8 weeks, and no authentication or mycoplasma testing were performed. For immortalization, primary astrocytes at passage 5 or 6 were cultured until 50–75% confluency and transfected with SV40 large T-antigen construct (18) followed by selection with 500μg/ml G418 (Sigma) until resistant colonies were formed. RPE1 hTert cells were obtained from ATCC and cultured according to ATCC recommendations. U87MG and U373MG were a kind gift from Dr. Daniel C. Flynn and were also maintained according to ATCC recommendations. GBM6 and 12 PDXs (19) were kindly provided by Dr. Jann Sarkaria (Mayo Clinic, Rochester, MN) through a shared MTA agreement, and no authentication or mycoplasma testing were performed. PDXs were used for cell culture isolation as previously described (20). A list of antibodies and their used applications is outlined in Table 1. shRNA constructs were obtained from Dharmacon and are outlined in Table 2. All primers were purchased from IDT Technologies, the sequences of which are reported in Table 3. MLN8237 (Selleckchem) and Tubastatin A (Selleckchem) were also used.

Western blotting

Western blotting was performed using standard procedures (21). Primary antibodies that were used are outlined in Table 1. Secondary anti-mouse and anti-rabbit HRP-conjugated antibodies (Jackson ImmunoResearch Labs) were diluted 1:10,000 followed by chemiluminescence-based detection with HyGLO™ (Denville Scientific). Bands were quantified using the digital electrophoresis documentation and image analysis software GeneTools (Syngene Corp.) with signal intensity normalized to α-tubulin.

Immunofluorescent cell analysis
Cells were processed as previously described (13). Primary antibodies that were used are outlined in Table 1. Secondary antibodies included AlexaFluor 488, 555, and 647 (ThermoFisher). Images were captured using a standard setting by an LSM510 confocal microscope (Zeiss) (21). All images represent whole-cell 3D reconstructed projections with 0.4μm steps. All quantifications were done using ImageJ (NIH).

**KIF2C cloning and cell lines generation**

KIF2C cDNA was purchased from PlasmID, PCR-amplified, and cloned into pEGFP (Clontech) vector between EcoRI and Xhol restriction sites. For inducible expression, EGFP-KIF2C fusion cDNA was cloned into pLUTZ lentivirus vector between AgeI and Xhol restriction sites (22). All constructs were validated by sequencing.

Lentiviral particles were produced as previously described (13). Cells were infected and selected with correspondent antibiotics until stable clones were formed.

**Cell growth/proliferation analysis**

Cell growth rate was determined using semi-automated cell counting in ImageJ (NIH). Cells were plated at 1x10^4 cells per well and grown in the specified conditions for five days, fixed with methanol, and stained with Hoechst33342. Four random 10x fields per well were analyzed with at least three replicates per independent experiment; each graph represents at least three independent experiments.
Results

**KIF2C overexpression drives cilia disassembly in an AURKA-dependent manner.**

To test whether overexpression of KIF2C can cause loss of primary cilium, we generated RPE1-hTert and human immortalized astrocytes with inducible overexpression of GFP-tagged KIF2C. In both cell lines, overnight induction of KIF2C expression under ciliated, serum pre-starved conditions resulted in robust disassembly of primary cilia (Fig.1A, B). To test if cilium disassembly was KIF2C dose-dependent, time course experiments with limited KIF2C induction times were performed. The time course experiment revealed robust KIF2C dose-dependent disassembly of primary cilia (Fig.1C-D).

To test if AURKA plays a role in KIF2C-driven cilia disassembly, a small molecule inhibitor highly specific for AURKA called MLN8237 was used. Inhibition of AURKA and simultaneous induction of KIF2C significantly attenuated KIF2C-driven cilia disassembly (Fig.1E), suggesting that AURKA activity is required. Interestingly, KIF2C was noted to be present inside the primary cilium in several cells, and its presence was associated with decreased acetylated tubulin staining in the same area (Fig.1F). These data argue that KIF2C enters primary cilium prior to disassembling it.

**Ciliated cells are likely to be more a differentiated cell population within GBM.**

GBM tumor cells have decreased ciliation, but nevertheless up to 10% of GBM tumor cells possess primary cilia in vivo (23). This was confirmed for two PDX-derived GBM primary cell lines GBM6 and GBM12 (Study 1); these cell lines represent classical and mesenchymal subtypes of GBM, respectively, and were chosen due to their high expression of AURKA and KIF2C and the worst prognosis. To test if the ciliated population of GBM cells had any associated phenotype, Sox2 and CD44 expression was analyzed. Sox2 is enriched in self-renewing neural progenitor cells (24), and its loss in GBM tumor-initiating cells causes abrogation of proliferation and tumorigenicity (25). CD44 is highly enriched in neural stem cells (26). The ciliated population of both GBM6 and 12 had only about 5% CD44-positive and 60% Sox2-positive cells, versus 40% and 80% in non-
ciliated cells, respectively (Fig.2A-C), suggesting that this population is more differentiated and less proliferative.

**Depletion of KIF2C or inhibition of AURKA inhibit GBM cell proliferation and restore ciliation.**

To test if KIF2C has any effect on the proliferation of GBM cells, we generated U87MG cells with stable shRNA-driven depletion of KIF2C (Fig.3A). All cell sublines had at least an 80% depletion of KIF2C, and proliferated significantly slower compared to the control cell line (Fig.3B). Since AURKA activity is required for KIF2C-driven cilia disassembly, it was tested whether the inhibition of AURKA can restore ciliation. Inhibition of AURKA for 24h with 50nM of MLN8237 was sufficient to cause a twofold increase in the ciliation of U87MG cells (Fig.3C) and also inhibit proliferation (Fig.3D). In PDX-derived GBM primary cells, incubation with MLN8237 for 24h was sufficient to increase ciliation of GBM6 cells up to 60%, as compared to 10-20% in the DMSO control group (Fig.3E). Interestingly, there were no changes in the total number of mitotic figures, however, half of the mitotic figures in MLN8237-treated cells represented characteristic abnormalities such as monopolar spindles (Fig.3F-G).
Future directions

Validation of GFP-KIF2C data with untagged KIF2C.

Data obtained from this study indicates that overexpression of GFP-KIF2C is sufficient to induce cilia disassembly (Fig.2), however, the level of overexpressed protein is much higher than the endogenous KIF2C level (Fig.2C). This can be explained by decreased depolymerization activity of EGFP-KIF2C (27) or the potential suppression of EGFP-KIF2C cilia entry due to size exclusion (28). To address this issue, KIF2C cDNA was cloned into pLUTZ vector between EcoRI and XhoI restriction sites, allowing for the inducible expression of KIF2C without a tag. Utilization of this construct will allow the confirmation of previously obtained results, and clarify if KIF2C triggers cilia disassembly in a more physiological range. It is expected that lower levels of KIF2C trigger cilia disassembly, as well as more abundant KIF2C entry into the cilium.

Evaluating the effects of S715 phosphorylation on KIF2C activity in vivo.

To test whether phosphorylation status of KIF2C at the S715 site has an effect on cilia disassembly, we generated a series of KIF2C mutants: KIF2C-S715A (phosphor-dead), KIF2C-S715E (phosphor-mimicking) and KIF2C-KVD (microtubule disassembly-impaired (29)) in pLUTZ vector (Fig.4A). Utilization of these constructs will allow for evaluation if S715 phosphorylation effects the ability of KIF2C to disassemble primary cilia. It is expected that KIF2C-S715E will be more effective in cilium disassembly than KIF2C-wt, while KIF2C-S715A will be less effective in cilium disassembly than KIF2C-wt. KIF2C-KVD will be utilized as negative control, since its overexpression is not expected to produce any effect on primary cilia. In addition, since KIF2C-KVD is supposed to be targeted to the cilium as well as KIF2C-wt, it is expected to see accumulation of KIF2C-KVD at the tip/along the primary cilium upon overexpression.

Evaluating the effects of S715 phosphorylation on KIF2C depolymerization activity in vitro.

To test whether the phosphorylation status of KIF2C at the S715 site has an effect on in vitro microtubule depolymerization activity, cDNA for KIF2C wt, KIF2C S715A, S715E and KVD) was cloned in pcDNA3.1 6His-Flag vector (Fig.4B). This system allows to
express KIF2C and the mutants in HEK293T cells (Fig.4C). Future plans call for purifying
the indicated proteins and using them for in vitro microtubule depolymerization assays
(30). It is not expected to see any difference in depolymerization activity between KIF2C-wt, KIF2C-S715A, and KIF2C-S715E, since tubulin available on the market consists of a
mixture of tyrosinated and detyrosinated isoforms. To evaluate the substrate preference
of KIF2C and its mutants, tyrosinated and detyrosinated tubulin dimers will be purified
using previously described methodology (31). In experiments with tyrosinated tubulin, it
is expected to see strong disassembly with KIF2C-wt, KIF2C-S715A, and KIF2C-S715E,
while detyrosinated tubulin is predicted to be more resistant to KIF2C-wt and KIF2C-
S715A (17), but more sensitive to KIF2C-S715E (15).

Evaluating the effects of KIF2C and AURKA depletion on the ciliation status of
GBM PDXs in vivo and in vitro.

To test whether depletion of KIF2C can restore ciliation in GBM PDXs, previously
validated shRNA against KIF2C (Fig.3) will be subcloned from pGIPZ vectors into pTRIPZ
vectors according to the manufacturer protocol to allow for inducible KIF2C depletion.
Inducible shRNA against KIF2C will be introduced in GBM6 and GBM12 primary cultures
and selected with puromycin. Selected cells will be injected into NSG mice for PDX
amplification as described previously (20). Amplified PDXs will be validated for KIF2C
depletion and used for in vivo and in vitro assessment of ciliation and proliferation. It is
expected that primary cilia in GBM PDXs will be restored and severely suppress
proliferation both in vitro and in vivo. Since the study data indicates that KIF2C-driven cilia
disassembly is AURKA dependent (Fig.1E), inhibition of AURKA in conjunction with
KIF2C depletion will be tested for their combined ability to restore ciliation and inhibit
cancer cell proliferation. It is expected that better primary cilia restoration will occur with
combination of AURKA inhibition and KIF2C depletion than with KIF2C depletion alone,
since AURKA activation can initiate HDAC6-dependent cilia disassembly (13).

Development of small molecule inhibitor for KIF2C.

To develop an anti-KIF2C specific inhibitor, virtual screen of compounds was
performed utilizing the publicly available crystal structure of the KIF2C motor domain
The 11 compounds (Table 4) with the highest fitting scores from this screen will be utilized in *in vitro* microtubule depolymerization assays. The compounds with the best ability to inhibit KIF2C-driven depolymerization will be tested further for their ability to inhibit KIF2C-driven cilia disassembly in cells, along with their effect on cell viability. Compounds showing the best results in these assays will be tested in their ability to restore primary cilium and suppress proliferation of PDX GBMs *in vitro* and *in vivo*. 
**Discussion**

Loss of the primary cilium seems to have a significant role in maintaining a highly proliferative phenotype in cancer (7, 8). At the same time, inhibition of primary cilia formation does not play a significant role in GBM tumor cell proliferation both *in vitro* and *in vivo* (27), and moreover, these findings argue that these cells are more differentiated (Fig.2). Targeting cancer cells in order to restore primary cilia is therefore expected to dampen proliferation and force re-differentiation of the cancer cells. Currently, the exact machinery participating in the disassembly of primary cilia has remained unknown, but this study establishes that KIF2C can enter primary cilium and promote disassembly in an AURKA-dependent manner. Targeting of either KIF2C or AURKA significantly affects proliferation of cancer cells. Elucidation of AURKA and KIF2C interactions that help promote primary cilia disassembly will allow for the development of new targeted therapies by preventing cilia loss of cancer cells.
References


Fig. 1. KIF2C overexpression drives cilia disassembly in an AURKA-dependent manner.

(A) Representative image of RPE1-hTert cells with (left-bottom corner) and without overexpression of GFP-KIF2C, stained for acetylated α-tubulin (AcTub, cilium marker) and KIF2C; scale bar – 10μm. Arrow indicates primary cilium. (B) Quantification of cilium in cells with (Dox+) without (Dox-) induction of EGFP-KIF2C expression as in (A) upon 24h of serum starvation; 300 cells total, 100 cells in each of 3 independent experiments; Student’s t-test, p<0.05. (C) Western blot of KIF2C in RPE1-hTert cells after 24h of serum starvation and induction of EGFP-KIF2C expression for the indicated number of hours. (D) Quantification of cells forming primary cilium upon induction of GFP-KIF2C expression
for the indicated number of hours as in (C); 300 cells total, 100 cells in each of 3 independent experiments; one-way ANOVA with Dunnett’s post hoc test, $p<0.05$. (E) Quantification of cells forming primary cilium as in (B) upon induction of GFP-KIF2C expression for 16h in the presence or absence of 50nM MLN8237; 300 cells total, 100 cells in each of 3 independent experiments; one-way ANOVA with Dunnett’s post hoc test, $p<0.05$. (F) Representative image of the primary cilium in human astrocytes after 48h of serum starvation, followed by 8h induction of GFP-KIF2C expression, stained for acetylated α-tubulin (AcTub, cilium marker) and KIF2C; scale bar – 10μm. Arrow indicates KIF2C accumulation in primary cilium.
Fig. 2. Stem-cell/differentiation marker status of ciliated cells is different from cells without primary cilia.

(A) Representative image of GBM6 and GBM12 cells with and without primary cilia stained for acetylated α-tubulin (AcTub, cilium marker), γ-tubulin (γTub, basal body marker), and CD44 (neural stem-cell marker); scale bar – 10 μm. (B) Quantification of CD44+ cells as in (A); 200 cells total, 100 cells in each of 2 independent experiments; Student’s t-test, p<0.05. (C) Quantification of Sox2+ cells; 200 cells total, 100 cells in each of 2 independent experiments; Student’s t-test, p<0.05.
Fig. 3. Effects of KIF2C depletion and inhibition of AURKA on GBM cell proliferation and ciliation.

(A) Western blot of KIF2C in U87MG cells stably-expressing shRNA against KIF2C. (B) Growth curve of U87MG cells as in (A); slopes of the fitted lines significantly different in F-test, * \( p < 0.05 \) (C) Quantification of cilium in U87MG cells treated with 50nM MLN8237 or 15μM Tubastatin A; 500 cells total, 250 cells in each of 2 independent experiments; one-way ANOVA with Dunnett’s post hoc test, \( p < 0.05 \). (D) Growth curve of U87MG cells as in (C); slopes of the fitted lines significantly different in F-test, * \( p < 0.05 \). (E)
Quantification of GBM6 cells forming primary cilium in the presence of 50nM MLN8237; 300 cells total, 100 cells in each of 3 independent experiments; Student’s \(t\)-test, \(p<0.05\).

(F) Representative image of the mitotic figures in GBM6 cells as in (E). Top image depicts normal mitotic figure, and bottom image depicts abnormal, monopolar mitotic figure; stained for acetylated α-tubulin (AcTub, cilium marker) and DAPI; scale bar – 10μm. (G) Quantification of mitotic figures as in (E and F); 200 cells total, 100 cells in each of 2 independent experiments.
Fig. 4. KIF2C cloning and protein production.

(A) Map of pLUTZ KIF2C construct. (B) Map of pcDNA3.1 6xHis-Flag KIF2C construct. (C) Western blot of 6xHis-Flag-KIF2C expressed in HEK293T cells. Cells were lysed in phosphate-buffered saline with 15mM imidazole.
### Table 1.

<table>
<thead>
<tr>
<th>target</th>
<th>cat.#</th>
<th>host species</th>
<th>company</th>
<th>application</th>
<th>dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>acetylated alpha tubulin</td>
<td>T6793</td>
<td>mouse</td>
<td>Sigma</td>
<td>IF</td>
<td>1:1000</td>
</tr>
<tr>
<td>gamma tubulin</td>
<td>sc-7396</td>
<td>goat</td>
<td>Santa Cruz</td>
<td>IF</td>
<td>1:500</td>
</tr>
<tr>
<td>alpha tubulin</td>
<td>16199</td>
<td>mouse</td>
<td>Sigma</td>
<td>WB</td>
<td>1:40000</td>
</tr>
<tr>
<td>CD44</td>
<td>sc-9960</td>
<td>mouse</td>
<td>Santa Cruz</td>
<td>IF</td>
<td>1:400</td>
</tr>
<tr>
<td>Sox2</td>
<td>3579S</td>
<td>rabbit</td>
<td>Cell Signaling Technology</td>
<td>IF</td>
<td>1:400</td>
</tr>
<tr>
<td>KIF2C</td>
<td>sc-81305</td>
<td>mouse</td>
<td>Santa Cruz</td>
<td>IF, WB</td>
<td>1:200, 1:1000</td>
</tr>
</tbody>
</table>

### Table 2.

<table>
<thead>
<tr>
<th>name</th>
<th>clone ID</th>
<th>targeting sequence</th>
<th>vector</th>
<th>company</th>
</tr>
</thead>
<tbody>
<tr>
<td>shKIF2C#1</td>
<td>V3LHS_357508</td>
<td>AAAACTACTGTCATACTCCT</td>
<td>pGIPZ</td>
<td>Dhharmacon</td>
</tr>
<tr>
<td>shKIF2C#2</td>
<td>V3LHS_357509</td>
<td>TGGAGTTGACGGATCTCCG</td>
<td>pGIPZ</td>
<td>Dhharmacon</td>
</tr>
<tr>
<td>shKIF2C#3</td>
<td>V2LHS_78032</td>
<td>TTATTTGCAGTCGTCACTG</td>
<td>pGIPZ</td>
<td>Dhharmacon</td>
</tr>
</tbody>
</table>

### Table 3.

<table>
<thead>
<tr>
<th>name</th>
<th>sequence</th>
<th>company</th>
</tr>
</thead>
<tbody>
<tr>
<td>EcoRI-Kif2C</td>
<td>ATTGAATTCCATGGCCATGGACTCG</td>
<td>IDT Technologies</td>
</tr>
<tr>
<td>Kif2C-XhoI</td>
<td>ATTCTCGAGTCGTCGACTGCGG</td>
<td>IDT Technologies</td>
</tr>
<tr>
<td>compound ID</td>
<td>compound name</td>
<td>company</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>7693705</td>
<td>2-{2-[(5-hydroxy-6-methyl-1,2,4-triazin-3-yl)thio]ethyl}-1H-isoindole-1,3(2H)-dione</td>
<td>ChemBridge</td>
</tr>
<tr>
<td>7657128</td>
<td>4-(3-[(4-(2-hydroxyethyl)-1-piperazinyl)sulfonyl]-4-methylphenyl)-2-methyl-1(2H)-phthalazinone</td>
<td>ChemBridge</td>
</tr>
<tr>
<td>11300854</td>
<td>6-((4-butyl-1H-1,2,3-triazol-1-yl)methyl)piperidin-1-yl)carbonyl-1H-indole</td>
<td>ChemBridge</td>
</tr>
<tr>
<td>63713617</td>
<td>N-(2,1,3-benzothiadiazol-5-ylmethyl)-N-methyl-1H-pyrazole-3-carboxamide</td>
<td>ChemBridge</td>
</tr>
<tr>
<td>73545990</td>
<td>3-[2-[4-(2-fluorobenzyl)piperidin-1-yl]-2-oxoethyl]dihydropyrimidine-2,4(1H,3H)-dione</td>
<td>ChemBridge</td>
</tr>
<tr>
<td>61771203</td>
<td>3-(2-fluorophenyl)-N-(imidazo[1,2-a]pyrimidin-2-ylmethyl)-1H-pyrazole-5-carboxamide</td>
<td>ChemBridge</td>
</tr>
<tr>
<td>97609998</td>
<td>2-amino-4-[5-(1H-pyrazol-3-yl)-2-thienyl]-6-(1H-pyrrol-3-yl)nicotinonitrile</td>
<td>ChemBridge</td>
</tr>
<tr>
<td>82375256</td>
<td>N-[2-[5-amino-1,3,4-thiadiazol-2-yl]ethyl]-5-(2-fluorophenyl)pyrazolo[1,5-a]pyrimidin-7-amine</td>
<td>ChemBridge</td>
</tr>
<tr>
<td>80994660</td>
<td>5-[(2-dibenzo[b,d]furan-4-yl-1H-imidazol-1-yl)methyl]-1,2,4-oxadiazole-3-carboxamide</td>
<td>ChemBridge</td>
</tr>
<tr>
<td>22763338</td>
<td>4-(2,6-dimethyl-3-pyridinyl)-N-methyl-N-[(3-(3-pyridinyl)-5-isoxazolyl)methyl]-2-pyrimidinamine</td>
<td>ChemBridge</td>
</tr>
<tr>
<td>81086871</td>
<td>(1-methyl-1H-imidazol-2-yl)(3-[6-(1H-pyrazol-1-yl)pyrimidin-4-yl]phenyl)methanone</td>
<td>ChemBridge</td>
</tr>
</tbody>
</table>
General Discussion

The primary cilium is a crucial organelle for the transduction of multiple signaling cascades (1-3). Loss of primary cilia is associated with an increase in cell proliferation in some cell types (3, 4), while suppressing cell proliferation in others (5, 6). In the majority of cancer types, including GBM, the length and number of primary cilia are significantly reduced or lost (7-10). Overall, the studies documented in this dissertation present multiple novel insights into the role of the primary cilium in the regulation of normal and cancer cell proliferation and in the mechanisms of cilia disassembly. In Study 1, it was demonstrated that the loss of primary cilia promotes proliferation of human astrocytes in a growth factor-dependent manner. For the first time, it was demonstrated that spatio-temporal characteristics of the cellular response to growth factors are drastically altered upon the loss of primary cilia. Previously, PDGF-AA signaling through PDGFRα was reported to be lost in deciliated fibroblasts (11), and IGF1R signaling was significantly reduced (12), thus an increase in proliferation upon the loss of primary cilia is a somewhat unexpected phenomenon. Other RTKs such as EGFR, FGFR, and Tie1/2 were noticed to localize to primary cilia (13-17), but the significance of this is unknown. In addition, different GPCRs can accumulate in the primary cilium (18, 19) along with their downstream signaling components (20, 21). Therefore, loss of cilia can interfere with multiple signaling cascades of various modalities, and systematic studies of signaling alterations are very scarce. In Study 1, LPA was established to be the main non-peptide growth factor responsible for the increased proliferation of astrocytes with disrupted ciliogenesis. For the first time, scrutinous analysis of the hyperproliferative phenotype in cells with an engineered loss of cilia was able to establish the underlining mechanism for increased proliferation. It was found that LPA-LPAR1 signaling is regulated by primary cilia. Loss of primary cilia promotes redistribution of LPAR1, which is normally localized to the cilium, and streamlines signaling through Gα12/Gq, thus increasing proliferation. Gα12 and Gq activation were previously reported to be implicated in cancer cell proliferation and cancer progression (22, 23). Furthermore, the LPAR1-Gα12 module specifically was reported to drive ovarian cancer cell proliferation (24). These findings suggest that primary cilia restricts LPA-LPAR1-driven Gα12/Gq activation. Loss of cilia in GBM cells highjacks LPA signaling to maintain a highly proliferative phenotype, rendering
them sensitive to inhibition of LPAR1. Utilization of a nanoparticle-based delivery of Ki16425, a small molecule inhibitor of LPAR1-3, as a monotherapy significantly decreased GBM growth in vivo. These results clearly indicate that inhibition of LPA signaling is a viable therapeutic option for GBM control in addition to standard care, especially in light of the implication of LPA in proliferation and migration/invasion (25, 26). Currently, the standard of care for GBM patients includes surgical resection of the tumor and a combination of radiation and chemotherapy (27). Unfortunately, the majority of patients experience recurrence of the disease within several months (28). Novel approaches in immunotherapy of GBM seem to be promising, but sustained responses are still rare (29). In part, this may be due to the prolonged lag period between the initiation of therapy and the tumor response (30), thus utilization of a tumor growth suppression agent in combination with an immunotherapeutic approach could be beneficial. Further studies are required to establish the possibility of combining LPAR inhibitors with conventional or immuno-based therapies. However, two LPAR inhibitors were recently used for clinical trials. BMS-986020, an LPAR1 inhibitor, is in Phase 2 clinical trials for idiopathic pulmonary fibrosis (NCT01766817); and SAR100842, an LPAR1 and 3 inhibitor, is in Phase 2 clinical trials for systemic sclerosis (NCT01651143). If the results of the current study can be replicated utilizing these compounds, GBM patient survival could be significantly improved, and disease control would become much easier. Based on Study 1’s findings, it would be expected to see a substantial increase in recurrence-free survival upon inhibition of LPA signaling in addition to the current standard of care.

Since loss of primary cilia alters a great number of signaling pathways, restoration of primary cilia in cancer cells could potentially restore proper signaling and induce re-differentiation. So far, several attempts were made to restore cilia in cancer cells, and results have been very promising (4, 31). However, since the mechanisms of cilia disassembly are still not fully understood, it is difficult to pursue. Thus, it is crucial to delineate the pathways involved in cillum loss. Study 2 focused on the role of KIF2C in the disassembly of cilia. It was found that KIF2C can enter and disassemble primary cilia in an AURKA-dependent manner. The differentiation/stem marker status of ciliated GBM cells was evaluated, which confirmed that the cilium is likely to promote re-differentiation along with halting proliferation. Finally, it was established that targeting of KIF2C and
AURKA drastically decreases proliferation of GBM cells, and moreover, AURKA inhibition can robustly restore primary cilia in these cells. AURKA is well known as a master regulator of cilia disassembly (32), as well as being an important mitotic regulator (33). Inhibition of AURKA, therefore, can suppress tumor growth in two ways: first, through direct inhibition of mitosis, and second, through restoration of the primary cilia. KIF2C is also involved in progression through mitosis, however depletion of KIF2C in non-transformed cells tends to generate a much milder phenotype than in cancer cells (34), indicating that KIF2C inhibition can potentially yield very little side effects. Further studies are required to elucidate the exact mechanism of AURKA–KIF2C cooperation in driving cilia disassembly. Unveiling the mechanisms of cilia disassembly in cancer cells will allow for the development of novel approaches for anti-cancer therapy. Restoration of primary cilia in cancer cells is expected to suppress proliferation and initiate re-differentiation, thus allowing for robust and prolonged disease control.

Appendix 1. Financial support

This research was supported by grants R21CA208875 (Elena N. Pugacheva), R01CA148671 (Elena N. Pugacheva) from the NIH/NCI, U54GM104942 (Werner J. Geldenhuys) from the NIGMS/NIH, WVU Cancer Institute Undergraduate Research Fellowship (Caryn L. Griffin), and “Let the Journey Begin” fund established by Erin Dunmire, WVU Cancer Institute. Andrey Bobko is supported by startup funding from WVCTSI. Naira V. Margaryan is supported by U54GM104942 from WVCTSI.

Imaging experiments were performed in the West Virginia University Microscope Imaging Facility, which has been supported by the WVU Cancer Institute and NIH grants P20RR016477/P20GM103434.
Appendix 2. Curriculum Vitae

Name: Yuriy Loskutov

Address: 2813 MBRCC, 1 Medical Center Drive
Morgantown, WV 26506
USA.
E-mail: ortoogon@gmail.com
Tel. (304)2930500

EDUCATION

<table>
<thead>
<tr>
<th>Degree</th>
<th>Institution</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSc</td>
<td>Saint Petersburg State University, Faculty of Biology and Soil Science, Universitetskaya Naberezhnaya, St. Petersburg, Russia, 199034</td>
<td>6/24/2008</td>
</tr>
<tr>
<td></td>
<td>Tel: 7(812)328-2000</td>
<td></td>
</tr>
<tr>
<td>MSc</td>
<td>Saint Petersburg State University, Faculty of Biology and Soil Science, Universitetskaya Naberezhnaya, St. Petersburg, Russia, 199034</td>
<td>6/23/2010</td>
</tr>
<tr>
<td></td>
<td>Tel: 7(812)328-2000</td>
<td></td>
</tr>
<tr>
<td>PhD</td>
<td>West Virginia University, Department of Biochemistry, 1 Waterfront Pl, Morgantown, WV 26501.</td>
<td>11/13/2017</td>
</tr>
<tr>
<td></td>
<td>Tel: (304) 293-2121</td>
<td></td>
</tr>
</tbody>
</table>
# RESEARCH EXPERIENCE

<table>
<thead>
<tr>
<th>Graduate student</th>
<th>10/12/2012-11/13/2017</th>
<th>Research subject:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>West Virginia University,</strong>&lt;br&gt;Department of Biochemistry&lt;br&gt;1 Medical Center Drive, HSC-S, MBRCC-2813, Morgantown, WV, 26506&lt;br&gt;Tel: 304-293-0500</td>
<td></td>
<td>Investigating the role of primary cilia and associated signaling cascades in maintaining highly proliferative phenotype of glioblastoma, using primary cells and patient derived platforms. Devising novel therapeutic strategies to treat glioblastoma, based on inhibition of the abnormal growth factor signaling initiated by loss of primary cilia.</td>
</tr>
</tbody>
</table>

**Supervisor:** Elena N Pugacheva, Ph.D  
Associate Professor, Biochemistry and WVU Cancer Institute,  
Adjunct Assoc.Professor Radiation Oncology  
Co-leader of Breast Cancer Research Program  
PDX Core Facility Director HSC,  
West Virginia University School of Medicine  
Health Sciences Center  
1 Medical Center Drive, Rm.2832, Morgantown, WV, 26506-9300.  
Tel: (304)293-5295

<table>
<thead>
<tr>
<th>Research Scholar</th>
<th>09/28/2010-10/12/2012</th>
<th>Research subject:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>West Virginia University,</strong>&lt;br&gt;Department of Biochemistry&lt;br&gt;1 Medical Center Drive, HSC-S, MBRCC-2813, Morgantown, WV, 26506&lt;br&gt;Tel: 304-293-0500</td>
<td></td>
<td>Identification of novel targets of AURKA, involved in primary cilia disassembly during cell cycle. Determine the role of NEDD9 adhesion adaptor protein in invasion of breast cancer cells <em>in vitro</em> and <em>in vivo</em> using cell lines and mouse model, investigating the</td>
</tr>
</tbody>
</table>

**Supervisor:** Elena N Pugacheva, Ph.D
Associate Professor, Biochemistry and WVU Cancer Institute,
Adjunct Assoc.Professor Radiation Oncology
Co-leader of Breast Cancer Research Program
PDX Core Facility Director HSC,
West Virginia University School of Medicine
Health Sciences Center
1 Medical Center Drive, Rm.2832, Morgantown, WV, 26506-9300.
Tel: (304)293-5295

<table>
<thead>
<tr>
<th>Junior scientist</th>
<th>2009-06/01/2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pavlov Institute of Physiology, 6 Nab. Makarova, 199034 St.Petersburg, Russia Tel.: 7(812) 3280701</td>
<td><strong>Research subject:</strong> Investigating the interaction between nervous and immune systems; TLR4 expression in enteric neurons following LPS challenge.</td>
</tr>
<tr>
<td><strong>Supervisor:</strong> Soukhova Galia, PhD Senior Scientist, Pavlov Institute of Physiology, 6 Nab. Makarova, 199034 St.Petersburg, Russia Tel:7(812)783-1030 <a href="mailto:gksouk@mail.ru">gksouk@mail.ru</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Undergraduate student-researcher</th>
<th>2006-2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Institute of Experimental Medicine, 12 Academic Pavlov str, St.Petersburg, Russia, 197376 Tel.: 7(812)2346868</td>
<td><strong>Research subject:</strong> Interaction between nervous and immune systems; studies dedicated to preproorexin gene expression in the hypothalamic cells of rats after LPS challenge.</td>
</tr>
<tr>
<td><strong>Supervisor:</strong> Novikova Natalia, Ph.D. Senior Staff Scientist, Institute of Experimental Medicine,</td>
<td></td>
</tr>
</tbody>
</table>
12 Akademic Pavlov str,
St. Petersburg, Russia, 199034
Tel: 7(812)234-0764
novikiem@gmail.com

AWARDS AND HONORS

<table>
<thead>
<tr>
<th>Award</th>
<th>Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSc diploma with honors</td>
<td>2008</td>
</tr>
<tr>
<td>MSc diploma with honors</td>
<td>2010</td>
</tr>
<tr>
<td>Van Liere Memorial Convocation and HSC Research Day, First Place Basic Science Year 5 Poster Presentation</td>
<td>2017</td>
</tr>
</tbody>
</table>

PROFESSIONAL SOCIETIES

<table>
<thead>
<tr>
<th>Role</th>
<th>Society</th>
<th>Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Associate Member</td>
<td>American Association for Cancer Research (AACR)</td>
<td>2013-current</td>
</tr>
</tbody>
</table>

TECHNICAL SKILLS

**Bacterial cell culture:**
Preparation and propagation of cultured bacteria, transformation of bacteria cells. Preparation of chemically competent cells suitable for molecular cloning (DH5α) and protein production (BL21).

**Mammalian cell culture:**
Mammalian cells (including normal epithelial, fibroblast, astrocytes and cancer cell lines), generation of stable transgene expressing cell lines, cell lines with shRNA or CRISPR/Cas9-based depletion/knockout. Viral stock preparation and infection. Cell proliferation, adhesion and invasion assays in 2D and 3D matrix cultures.

**Molecular biology:**
PCR techniques, gel electrophoresis, genomic/plasmid DNA and RNA purification, site directed mutagenesis, DNA ligation/molecular cloning, expression and purification of proteins from bacterial and mammalian cells, in vitro kinase assay, protein labeling, immunoprecipitation, Western blotting, enzyme linked immunosorbent assay (ELISA), fluorescence-activated cell sorting (FACS). Design of custom lentivirus-based vectors.

**Imaging:**
Live cell imaging systems: confocal and bright field microscopy, confocal data analysis software and 3D deconvolution, imaging of primary cilia and vesicular transport. Focal
adhesion and actin dynamics using fluorescently labeled proteins. Fluorescence recovery after photobleaching (FRAP) and subsequent data analysis. 

_in vivo_ imaging techniques: ultrasound imaging using VeVo system, luciferase based xenograft imaging using IVIS system, contrast enhanced MRI using ICON system; and subsequent data analysis.

**Animal models:**
Solid knowledge of rodent physiology, animal handling, particularly laboratory rats and mice; maintenance of mouse colony, including managing transgenic mouse strains; breast and glioblastoma xenograft tumor implantation, tumor bearing animal care and tumor burden evaluation. Rodent surgeries: estrogen pellets implantation/removal, tumors implantation/resection (subcutaneous and orthotopic), stereotactic guided intracranial injections. Behavioral evaluation in mice, including Morris water maze and open field test. Experienced in animal studies protocol development, management and review.

**Patient derived tumor models:**
Handling patient samples, cataloging and processing new samples; surgical implantation of the patient tumors, maintenance and support of patient-derived xenograft colony maintenance. Designing and running of the therapeutic compound screens in patient-derived xenograft transplanted mice.

**Large data analysis:**
Experienced with TCGA data mining and analysis, as well as RNAseq data analysis and interpretation (as part of the bioinformatics workshop class by Dr. Peter Stoilov)

**Miscellaneous:**
Proficient in supplies ordering, lab maintenance, teaching of new students. Project development experience, grants and manuscripts writing and preparation for publication.

**Other Skills:**
Proficient with Microsoft Office package, Vector NTI, ImageJ, Adobe Photoshop/GIMP and Illustrator/InkScape, GraphPad Prism, basic knowledge of R.

---

**RECOMMENDATIONS**

For further recommendations, please, contact:

Elena Pugacheva, PhD

Associate Professor, Biochemistry and WVU Cancer Institute,

Adjunct Assoc.Professor Radiation Oncology

Co-leader of Breast Cancer Research Program

PDX Core Facility Director HSC,

MBRCC 2813, 1 Medical Center Dr.,

Morgantown, 26506, WV, USA

Tel: 304-293-5295, epugacheva@hsc.wvu.edu
Michael D. Schaller, PhD
    Chairman, Department of Biochemistry, WVU
    HSCN 3124, 1 Medical Center Dr.,
    Morgantown, 26506, WV, USA
    Tel: 304-293-9514, mschaller@hsc.wvu.edu

Michael Ruppert, MD/PhD
    Professor, Department of Biochemistry, WVU,
    Jo and Ben Statler Eminent Scholar & Chair in Breast Cancer Research
    Co-Director, Program in Breast Cancer Research, MBRCC
    BMRC-Erma Byrd 212, 1 Medical Center Dr.,
    Morgantown, 26506, WV, USA
    Tel: 304-293-5246, mruppert@hsc.wvu.edu

Peter Stoilov, PhD
    Associate Professor, Department of Biochemistry, WVU,
    HSCN 3131 C, 1 Medical Center Dr.,
    Morgantown, 26506, WV, USA
    Tel: 304-293-6334, pstoilov@hsc.wvu.edu

Karen Martin, PhD
    Research Assistant Professor, Department of Microbiology, Immunology & Cell Biology, WVU,
    Research Associate Professor, Department of Neurobiology and Anatomy, WVU
    Scientific and Technical Director, Microscope Imaging Facility, WVU
    Scientific and Technical Director, Animal Models & Imaging Facility, WVU
PUBLICATIONS


